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ABSTRACT: With the emergence of multi-drug-resistant strains
of Mycobacterium tuberculosis, there is a pressing need for new oral
drugs with novel mechanisms of action. A number of scaffolds with
potent anti-tubercular in vitro activity have been identified from
phenotypic screening that appear to target MmpL3. However, the
scaffolds are typically lipophilic, which facilitates partitioning into
hydrophobic membranes, and several contain basic amine groups.
Highly lipophilic basic amines are typically cytotoxic against
mammalian cell lines and have associated off-target risks, such as
inhibition of human ether-a-̀go-go related gene (hERG) and IKr
potassium current modulation. The spirocycle compound 3 was reported to target MmpL3 and displayed promising efficacy in a
murine model of acute tuberculosis (TB) infection. However, this highly lipophilic monobasic amine was cytotoxic and inhibited the
hERG ion channel. Herein, the related spirocycles (1−2) are described, which were identified following phenotypic screening of the
Eli Lilly corporate library against M. tuberculosis. The novel N-alkylated pyrazole portion offered improved physicochemical
properties, and optimization led to identification of a zwitterion series, exemplified by lead 29, with decreased HepG2 cytotoxicity as
well as limited hERG ion channel inhibition. Strains with mutations in MmpL3 were resistant to 29, and under replicating
conditions, 29 demonstrated bactericidal activity against M. tuberculosis. Unfortunately, compound 29 had no efficacy in an acute
model of TB infection; this was most likely due to the in vivo exposure remaining above the minimal inhibitory concentration for
only a limited time.
■ INTRODUCTION
Mycobacterium tuberculosis,1 the causative agent of tuberculosis
(TB), can be fatal if not properly treated and disproportionately
affects the poor in developing countries. In 2015, TB became
the world’s most deadly infectious disease, killing 1.4 million
people (1.2 million HIV-negative and 0.3 million HIV-positive)
in 2019.2 The current 6 month treatment results in high default
rates, increased transmission, and drug resistance.3−5 In order
to reduce treatment length, TB treatments working through
novel mechanisms are needed.6−8 However, identifying novel
drugs remains a significant challenge, and high-quality leads are
still urgently required.9,10
Target-directed TB drug discovery programs have historically
been largely unsuccessful in delivering high-quality late-stage
leads.7 To address this issue, cell-based phenotypic screening
became a focus for identifying active starting points. Many of
the most potent phenotypic hits target membrane proteins such
as DprE1 and MmpL3 that are involved in cell wall
biosynthesis.11 MmpL3 is required for the export of trehalose
monomycolates (TMM) to the periplasmic space and outer
membrane of M. tuberculosis. A number of structurally diverse
putative MmpL3 inhibitor series have been reported.12−29
Several of these series inhibit MmpL3-mediated TMM export
but may also have pleiotropic effects targeting the proton
motive force.13
The scaffolds of MmpL3 inhibitors are typically lipophilic,
which facilitates partitioning into hydrophobic membranes, and
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several contain basic amine groups. Highly lipophilic basic
amines are typically cytotoxic against mammalian cell lines and
have associated off-target risks, such as inhibition of human
ether-a-̀go-go related gene (hERG) and IKr potassium current
modulation. One particular spirocyclic series has been reported
as a potential MmpL3 inhibitor following a phenotypic screen
of the GSK library against Mycobacterium bovis.19 Although
further exploration of this original hit identified compounds
with excellent in vivo activity against M. tuberculosis (3), the
series was discontinued because of concerns over safety related
to the lipophilicity and basic nature of the scaffold.30 Of note,
the original authors highlighted that further exploration may be
able to design around the series liabilities while retaining the
remarkable in vivo potency30
Herein, we report on a novel pyrazole spirocyclic amine
series (1 and 2) with a putative MmpL3 mechanism of action
that is structurally related to 3 (Table 1). The novel pyrazole
portion offered improved physicochemical properties, and
optimization led to identification of a zwitterionic series, with
improved selectivity over both HepG2 cytotoxicity and hERG
inhibition. The zwitterionic series retained potent M. tuber-
culosis whole cell activity, with large shifts against MmpL3
mutant strains. Unfortunately, the series representative with the
best overall properties, 29, failed to show efficacy in an acute
model of TB infection. As such, further work on this series was
put on hold. We feel that the approach presented indicates
useful insights into mechanisms for reduction of metabolism
and hERG liabilities while highlighting the challenge within
drug discovery of balancing these properties with potency.
■ RESULTS AND DISCUSSION
Structure−Activity Relationship. To identify novel anti-
tubercular agents, an aerobic whole cell phenotypic screen was
undertaken, evaluating the Eli Lilly corporate screening deck
against M. tuberculosis strain H37Rv. One of the outcomes of
this screen was the identification of a cluster of pyrazole-
containing spirocyclic amine analogues; the spirocyclic portion
of the molecule showed a clear structural resemblance to 3, a
previously reported spirocycle series (Table 1).19,30 The initial
hits had good anti-tubercular activity with a minimum
inhibitory concentration (MIC) of 0.22 and 0.14 μM for 1
and 2, respectively (Table 1). As the original spirocycle
compound was considered to be an MmpL3 inhibitor, we
tested the activity of these two compounds against a strain
containing a mutation in MmpL3 (F255L) and observed a large
shift in the MIC confirming the likely on-target activity (Table
1).
According to the literature, 3 had not been developed further
because “it suffered from a high clog P value, with the
consequent potential liabilities for further development”.19,30,31
Compounds 1 and 2 offered an attractive alternative to 3
because the central aromatic ring in both was a pyrazole not a
phenyl; this modification was predicted to reduce the clog
DpH7.4 by around 1 log unit. The reduced lipophilicity translated
into a better solubility forecast index andM. tuberculosis-derived
LLE,32−35 providing optimism for improving off-target
liabilities, metabolic stability, as well as solubility profile.
Unfortunately, as a result of the basic nature of the piperidine
group, hERG inhibition remained an issue for 1 and 2;
Table 1. In Vitro Profile of Early Hits against a Reported MmpL3 Inhibitor
confirmed hit 1 confirmed hit 2 GSK-SPIRO 3 early lead 4
MICa (μM) 0.22 0.14 0.083 0.11
MIC MmpL3 F255L mut. (μM) 31 16 1.7 2.6
hERGb,c IC50 (μM) 2.9
c 1.1c 3.1c 3.1c
HepG2d (μM) 36 32 20 38
LLE 4.5 4.5 3.0 4.3
SFI 5.2 5.5 7.1 5.4
kin. solubility (μM) >250 >250 39 >250
MW 379 373 475 373
clog DpH7.4 2.2 2.5 4.1 2.5
TPSA (Å2) 30 30 31 30
mouse Cle (mL/min/g) >50 >50 7.5 >50
human Clf (mL/min/g) ND ND 1.7 4.6
aMIC is the minimum concentration required to inhibit the growth ofM. tuberculosis (H37Rv) in liquid culture. All MIC values are an average of at
least two measurements. bhERG functional thallium flux inhibitory concentration (IC50).
chERG functional Q-patch inhibitory concentration
(IC50).
dHepG2 inhibitory concentration (IC50) is the concentration required to inhibit growth of HepG2 cells by 50%.
eIntrinsic clearance (Cli)
using CD1 mouse liver microsomes. fIntrinsic clearance (Cli) using pooled human liver microsomes. LLE is the lipophilic ligand efficiency; SFI is
the solubility forecast index; TPSA is the total polar surface area. Estimations of clog DpH7.4 and TPSA were calculated using StarDrop (http://
www.optibrium.com).
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moreover, despite the lower clog DpH7.4, both showed
unexpectedly high mouse microsomal clearance.
Initial emphasis for expansion of the confirmed hits 1 and 2
was placed on understanding the scope for improving hERG
channel inhibition and microsomal stability. The pyrazole of 1
and the spirocycle of 2 were combined to afford 4, which
showed marginally improved selectivity over the hERG
channel, although the mouse microsomal clearance remained
high (Tables 1 and 2). In addition, the human microsomal
metabolic stability was higher for 4 than the published molecule
Table 2. In Vitro Evaluation of Spirocycle Analogues
R1 MIC
a μM clog DpH7.4 hERG
a IC50 μM HepG2
a IC50 μM mouse Cli
a (mL/min/g)
4 phenyl 0.11 2.5 3.1a 38 >50
5 no group 4.7 1.7 >30a 28
6 6-fluorophenyl 0.16 2.7 3.5a 48 >50
7 7-fluorophenyl 0.12 2.7 4.7a 32 >50
8 6,7-difluorophenyl 0.69 2.8 1.8a 14 >50
9 6-CF3-phenyl >20 3.1 0.8
a 7 9
10 7,8-difluorophenyl 2.5 2.8 1.7a 16 >50
aSee Table 1 for explanation.
Table 3. In Vitro Evaluation of Spirocycle Analogues
R2 R3 MIC
a (μM) clog DpH7.4 hERG
a IC50 (μM) HepG2
a IC50 (μM) mouse Cli
a (mL/min/g)
11 phenyl OMe 0.12 2.5 2.1a 23 >50
12 phenyl CyPr 0.10 3.0 2.2a 22 >50
13 phenyl CHF2 0.20 3.1 3.6
a 15 >50
14 phenyl CF3 0.09 3.1 4.7
a 30 >50
15 4-(hydroxymethyl) phenyl Me 1.5 2.0 5.0a >50 8.5
16 4-methylphenyl Me 0.08 2.6 2.5a 11 >50
17 4-(trifluoromethoxy) phenyl Me 0.36 3.4 1.9a 8.6 7
18 6-methoxy pyridin-3-yl Me 0.37 2.0 3.5a >50 44
19 6-(difluoromethoxy)-pyridin-3-yl Me 0.21 2.5 0.52a 18 25
20 6-(trifluoromethyl) pyridin-3-yl Me 0.51 2.6 2.7a 42 10
21 2-benzoic acid Me >20 0.6 >30a >50 <0.5
22 3-benzoic acid Me 3.7 0.5 10.2a >50 1.6
23 4-benzoic acid Me 4.8 0.6 >30a >50 0.5
24 4-benzoic acid Et 0.77 0.9 >30a >50 1.1
25 4-benzoic acid iPr 3.8 1.4 >30a >50 1.2
26 4-benzoic acid tBu 5.5 1.3 >30a >50 1.1
27 4-benzoic acid CHF2 1.4 1.3 >30
a >50 0.7
28 4-benzoic acid CF3 0.65 1.5 >30
a >50 1
29 4-benzoic acid CyPr 0.66 1.2 >30a >50 1.1
30 4-benzoic acid CyBu 1.8 1.5 >30a >50 1.6
31 4-benzoic acid OMe 1.9 0.6 >30a >50 1.3
32 4-benzoic acid OEt 0.53 0.9 >30a >50 3.8
33 4-benzoic acid N-pyrrolidino- 13 1.3 >50 1.5
34 4-benzoic acid N-morpholino- >20 1.3 >50 <0.5
aSee Table 1 for explanation.
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3, although both values were lower than the equivalent mouse
data. As a first step to attempt to reduce metabolism of 4, a
mouse microsomal metabolite identification study was carried
out to evaluate why the pyrazole series had worse microsomal
stability than 3 despite a lower clog DpH7.4 (Table 1). This
showed that 4 was metabolized rapidly to four main metabolites
primarily involving hydroxylation. After a 3 min incubation in
mouse microsomes, only 29% of the parent ion remained, while
61% of the detectable ions were associated with three
metabolites that resulted from hydroxylation associated with
regions of the molecule around the spirocycle group (Table S1;
Figures S1 and S2). Because phenyl groups are known to be
prone to hydroxylation, which can be prevented by
fluorination,36 the phenyl substituent on the spirocycle was
replaced by a series of different fluoro-substituted phenyl
groups (Table 2). Unfortunately, compounds that retained
good MIC activity remained very unstable in mouse micro-
somes, while the compounds with improved metabolic stability
had significantly decreased potency (Table 2).
To examine the metabolic stability further, isoform-specific
cytochrome P450 studies were carried out on 4, evaluating
CYP3A4 and CYP2D6 as the two most abundant human
CYP450 enzymes. Pyrazole 4 was more rapidly cleared by
CYP2D6 bactosomes (0.34 min−1) than CYP3A4 bactosomes
(0.07 min−1). As the CYP2D6-active site is known to be smaller
in comparison to CYP3A4,37 it was proposed that increasing
the size of substituents on either the 5-methyl pyrazole or the
phenyl in 4 could potentially lead to a decrease in CYP2D6
metabolism and thereby improve the metabolic stability to be
more in line with the larger compound 3.
To test the above hypothesis, the structure−activity relation-
ship (SAR) around the methyl and phenyl substituents was
expanded. Initial modifications to the 5-methyl pyrazole had
little effect on MIC, hERG channel inhibition, or metabolic
stability (11−14), and so further exploration of this substituent
was put on hold. For the phenyl substituted compounds 15−
17, there was a trend toward improved metabolic stability, in
particular with the bulky OCF3 blocking group of 17 despite it
having a high clog DpH7.4 (Table 3). In an attempt to reduce or
maintain as low a clog DpH7.4 as possible, the SAR around a 1-
pyridyl substituent was explored. For the pyridyl-substituted
compounds 18−20, again there was a trend toward improved
metabolic stability, in particular with bulkier and more
lipophilic groups such as the CF3 in 20 (Table 3).
As an alternative phenyl substitution, the addition of a
carboxylic acid group was explored (Table 3). Such a
modification adds bulk, introduces polarity, and the presence
of a zwitterion has been shown previously to overcome hERG
channel inhibition.38 While the ortho-acid 21 was not tolerated,
the modest M. tuberculosis whole cell activity of 22 and 23 was
encouraging especially because the para-acid 23 showed a
dramatic improvement in the compound’s liabilities including
hERG channel inhibition, mouse metabolic stability, and
HepG2 cytotoxicity. Although the overall properties of 23
were an improvement on 4, this came at a significant reduction
in antibacterial potency (∼40 fold). To continue optimization
of 23, we reassessed modifications of the 5-methyl pyrazole as
these had been tolerated previously on 4. In general,
substitutions 29−34 were well tolerated, apart from cyclic
amines 33 and 34, with good profiles in relation to hERG
inhibition, mouse metabolic stability, and HepG2 cytotoxicity.
Substituted alkyl as well as fluoroalkyl resulted in notable
improvements in the whole cell potency for cyclopropyl 29,
trifluoromethyl 28, ethyl 24, and ethoxy 32 (Table 3).
Biological Profiling. Compound 29 was not cytotoxic to
HepG2 cells, grown in either glucose or galactose media, nor
the THP-1 macrophage-like cell line (data not shown). 29 had
good potency against intracellular bacteria in THP-1 cells [IC50
= 1.5 ± 1.3]. Compound 29 was also shown to retain good
activity against clinical samples from the four main lineages and
Table 4. Activity against M. tuberculosis Clinical Strains of Different Lineage and Resistancea
MIC90 (μM)
H37Rv N0157 L1 N0052 L2 N0004 L3 N0136 L4 INH-R2 RIF-R2
23 5.1 >50 7.3 24 9.6 8.6 13
29 0.78 2.8 2.2 5.2 2.4 0.37 0.76
rifampicin 0.01 0.01 0.01 0.01 0.01 0.01 >50
isoniazid ND ND ND ND ND >200 0.58
aMIC is the minimum concentration required to inhibit the growth of M. tuberculosis (H37Rv) in liquid culture L1 is TB lineage 1 and so forth.
Figure 1. Kill kinetics for 29 against replicating and nonreplicatingM. tuberculosis. Bacterial viability in the presence of compound was determined by
cfu over 28 days (A) under replicating conditions and (B) under nonreplicating conditions. The dashed lines represent the upper and lower limits of
detection.
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strains containing resistance mutations to either isoniazid or
rifampicin (Table 4).
Minimum bactericidal concentration (MBC) and kill kinetics
were evaluated under both aerobic (replicating) and starvation
(nonreplicating) conditions. Under replicating conditions, 29
showed concentration-dependent kill of M. tuberculosis with an
MBC of 3 μM (Figure 1A). At later stages, outgrowth was
observed because of either compound instability over long
incubation periods or the appearance of resistant mutants.
Under nonreplicating conditions, 29 showed no bactericidal
effect against M. tuberculosis (Figure 1B).
Compound 29 showed a 10-fold decrease in activity against
the MmpL3F255L strain of M. tuberculosis, indicating that it
retained an MmpL3-related mechanism of action. An impact on
this pathway was also indicated using a hypomorph strain
(P606-5C-mmpL3) that underexpresses MmpL3 when grown
in the absence of anhydrotetracycline (Figure 2). Initially, it was
confirmed that SQ109, a known inhibitor of MmpL3, was more
active against the hypomorph strain with a four-fold improve-
ment in MIC50, while ethambutol, a cell wall inhibitor targeting
a different pathway (arabinosyl transferases), was equally
effective against both the wild-type and hypomorph strains.
We tested two representatives from the series (4 and 23); both
showed significant shifts in potency, with the MmpL3
hypomorph being at least eight-fold more sensitive. These
data support the conclusion that, as shown in the literature for
3, the series works through an MmpL3-related mechanism.
In Vivo Analysis. Based on the hit to lead SAR,
representative compound 29 was selected for follow-up. A
fluorinated derivative, 35, was also prepared as such
modifications had been shown previously (Table 2) to not
have a detrimental effect on MIC activity but could potentially
improve metabolic stability and in vivo exposure. As expected,
35 had a similar MIC activity to 29 (Table 5). Although there
was no significant change in metabolic stability, neither mouse
nor human, the fluorination did result in an unexpected increase
in activity against the hERG ion channel. The in vivo exposure
of both compounds was evaluated in female C57BL/6 mice (n
= 3/dose level) (Table 5). Both compounds had moderate in
vivo blood clearance, moderate volume of distribution,
moderate half-life, and low bioavailability. Although the
Figure 2. Decreased MmpL3 expression results in hypersensitivity to the spirocycle series. Removal of anhydrotetracycline (atc) results in
transcriptional repression of mmpL3. Growth in the presence of a negative control ethambutol (A) and a positive control SQ109 (B) as well as
representative series compound, 4 (C) and 23 (D) are recorded relative to DMSO-treated samples. Data are representative of two independent
experiments.
Table 5. Biology and ADME/PK Profiles for Selected Best
Molecules
29 35
MICa μM 0.66 0.79
hERGa IC50 μM >30
a 10a
HepG2a μM >50 >50
clog DpH7.4 1.2 1.4
microsomal Cla mL/min/g 1.1 0.9
human micro Cla mL/min/g 0.6 0.5
C57 mouse PK at 3 mg/kg iv and 10 mg/kg po
Cmax po (ng/mL) 164 294
T1/2 (h) 2 2.6
AUC0−24 po (ng-min/mL) 20,728 36,486
Clb (mL/min/kg) 56 53
Vdss (L/kg) 2 3
% F 12 19
aSee Table 1 for explanation.
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exposure of 35 was greater than 29, it was not substantially
improved enough to make it worthwhile to risk the increase in
hERG channel inhibition. Therefore, further work focused on
29. As the initial preliminary pharmacokinetic analysis was done
on the free-base form of the molecule, a hydrochloride salt form
of 29 was prepared and evaluated at higher doses to determine
whether the compound was suitable for an in vivo efficacy
assessment. The HCl salt of 29 was dosed at 200 and 400 mg/
kg in 1% carboxymethylcellulose (CMC) generating Cmax values
of 22,266 and 85,278 ng/mL, respectively. Moreover, at both
the 200 and 400 mg/kg doses, the exposure, both total and free
(plasma Fu = 0.2), was above the reported MIC (0.66 μM/292
ng/mL) for >6 h.
Based on the results from the PK studies, 29 was assessed in
an acute mouse model of TB infection using Balb/c mice in a
direct comparison with the previously reported compound 3.30
As expected, 3 was very active in the study promoting a >2.5
log10 reduction in colony forming units (CFUs), reducing lung
burdens in infected mice near to or below the limit of detection
(Figure 3). This was similar to the control drug rifampicin given
at a dose of 20 mg/kg (Figure 3). In contrast, 29 showed no
appreciable reduction in lung CFUs relative to the untreated
control in this experiment. Plasma samples for PK from these
infected animals were taken during steady state at 1 and 24 h
after dosing. Although both compounds showed free plasma
concentrations well above MIC at 1 h post-dosing, only 3
remained above MIC for the full 24 h period. Thus, one
potential explanation for the difference in efficacy was
inadequate drug exposure above MIC for 29 compared to 3.
■ CHEMISTRY
Synthetic Routes. Synthesis of related spirocyclic amines
has been previously reported.19,39 The general synthetic routes
employed for the synthesis of pyrazole containing spirocyclic
amines are shown below (Scheme 1). The appropriately
substituted R1 aryls or heteroaryls were reacted with 1-[(4-
methoxyphenyl)methyl]piperidin-4-one to form 48, which was
then deprotected to form amine 49. An alternative route
involved reacting the appropriately substituted R1 aryls or
heteroaryls with the protected piperidin-4-one to form diols
40−43. Cyclic dehydration afforded 44−47, which were
deprotected to afford amines 50−53. Substituted pyrazole
aldehydes 70−77 were prepared from the esters 63−69
(Scheme S1 in Supporting Information) by reduction to the
alcohol and then oxidation to the aldehydes. R2- and R3-
substituted pyrazole esters 63−69 were prepared in three main
ways: from R3-substituted pyrazole 60, using copper-mediated
coupling of suitable R2 boronic acids, by cyclo-dehydration of
ethyl 4-(R3)-2,4-dioxo-butanoates 55−59 with R2-substituted
hydrazines, and by reaction of dimethyl but-2-ynedioate with
R2-substituted hydrazines. In the final step, reductive amination
with appropriate R2-and R3-substituted pyrazole aldehydes
70−77 afforded target compounds 1−14, 17, 18, 20, and 21.
Further Chan−Lam coupling of the NH pyrazole 78 with
appropriate boronic acids afforded target compounds 15, 16,
and 19.
For compounds containing a carboxylic acid moiety on the
phenyl ring attached to the pyrazole core, a different approach
was needed. For these compounds, some could be synthesized
by carrying the carboxylic acid through the synthesis protected
as an oxazoline (Scheme 2) and some by a late-stage conversion
from the bromide (Scheme 3). Carboxylic acid substituted
phenyl hydrazines could be reacted with suitable triketo
compounds to afford R3-substituted pyrazole esters 87, 88,
and 90−92. Because of carrying an ester in these molecules,
ester protection of the acid was not a plausible route at this
stage, and so to synthetically distinguish the different functional
groups, the acids were protected as oxazolines. Amide coupling
with ethanolamine followed by chlorination and cyclization
easily provided oxazolines 93−98, which could then be carried
through the synthesis without problem. Reduction to aldehydes
99−104 as before followed by reductive amination to 105−109
and simple deprotection with 2 M HCl afforded the target
compounds 22, 23, and 26−28. Compound 24 followed the
majority of this route; however, the carboxylate 95 was
synthesized via reaction of 4-aminobenzoic acid with ethyl 2-
chloro-3-oxo-butanoate and subsequent cyclization to the
pyrazole. Alternatively, when the substituted phenyl hydrazine
could be reacted with R3-substituted diethoxy diketo
compounds 81−83, then only one synthetic step was needed
to afford compounds 25, 29, 30, and 35.
The carboxylic acid compounds could also be realized from
the bromides. Reaction of 4-bromophenylhydrazines with
dimethyl but-2-ynedioate afforded pyrazole 110. Where the
desired R group was an alkoxy group, the hydroxyl moiety could
be simply alkylated. Where R3 was an amine, this was
introduced via a Vilsmeier reaction, followed by SNAr and
removal of the aldehyde, to form compounds 114−117. As in
the previous schemes, reduction to aldehydes 118−121
followed by reductive amination afforded spirocyclic amino
pyrazoles 122−125. In order to convert the bromide to
carboxylic acid, compounds 122−125 were carbonylated using
N-formylsaccharin as a source of carbon monoxide, which is
slowly released in situ as described in the literature.40 The acyl
fluoride formed in the reaction as a result of the caesium
fluoride base was quenched with H2O to form the final target
compounds 31−34. For all the compounds discussed in this
report, no alerts were found when they were processed through
a PAINS filter.
■ CONCLUSIONS
Following on from the previous publication of a spirocycle
series with potent inhibition of M. tuberculosis but limited by
safety concerns,30 the optimization of a related but novel
pyrazole spirocyclic amine is described. This report identified a
zwitterionic series, exemplified by lead 29 that when compared
to the original series, 3 had improved selectivity over HepG2, as
well as reduced hERG channel inhibition. As with the original
series, 29 was a putative MmpL3 inhibitor as large shifts against
MmpL3 mutant strains were observed. Although 29 has a better
Figure 3. Efficacy in a mouse model of acute TB infection. BALB/c
mice were infected with M. tuberculosis H37Rv via a low-dose aerosol
exposure. Treatment was started 7 days post-aerosol and continued for
12 consecutive days. Drugs were administered once daily by oral
gavage at 100 mg/kg (3) and 300 mg/kg (29).
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selectivity profile than the earlier molecules, this came at the
expense of reduced potency; as such, while 3 had excellent
activity in an acute in vivo model of TB infection, 29 was found
not to be efficacious in the same model. The lack of efficacy of
29 was hypothesized to be as a result of the need for improved
in vivo exposure to ensure maximum coverage above the MIC.
Thus, despite the original authors highlighting the possibility of
eliminating series liabilities while retaining the remarkable in
vivo potency,30 given the complexity of balancing metabolic
stability and hERG channel inhibition with MIC activity for this
series, no further work was planned to try and improve
exposure.
■ EXPERIMENTAL SECTION
Determination of MIC. MICs were determined against M.
tuberculosis H37Rv (ATCC 25618) and mutant strains grown
in Middlebrook 7H9 medium containing 10% v/v OADC
(oleic acid, albumin, dextrose, and catalase) supplement
(Becton Dickinson) and 0.05% w/v Tween 80 (7H9-Tw-
OADC) under aerobic conditions as previously described.
Bacterial growth was measured after 5 days of incubation at 37
°C.41
MmpL3 Hypomorph. Wild-type H37Rv and P606-5C (in
which the native copy of mmpL3 was replaced with kanR and a
tetracycline-regulated copy of mmpL3 was inserted at the att-L5
site and also contains zeoR) were each cultured in 10 mL of
Middlebrook 7H9 [with kanamycin and zeocin at 25 μg/mL
and anhydrotetracycline (atc) at 500 ng/mL for the mutant
strain] supplemented with 0.2% (v/v) glycerol, 0.05% (v/v)
tyloxapol, and ADNaCl (0.5% [w/v] BSA, 0.2% [w/v] dextrose,
and 0.85% [w/v] NaCl) in a 25 cm2 tissue culture flask with a
vented cap. After approximately 7 days at 37 °C and 5% CO2 in
Scheme 1. General Synthetic Routes for the Synthesis of Compounds 1−21a
aReagents and conditions: (i) BH3.THF, THF, 100 °C, and 1 h; (ii) nBuLi, THF, −78 °C, 1 h, then tert-butyl 4-oxopiperidine-1-carboxylate −78
°Crt, and 18 h; (iii) MeSO2Cl, Et3N, DCM, reflux, and 1.5 h; (iv) TFA, DCM, and 18 h; (v) 1-[(4-methoxyphenyl)methyl]piperidin-4-one,
MeSO3H, PhMe, reflux, Dean−Stark, and 18 h; (vi) 1-chloroethyl carbonochloridate, DCM, 0 °C then MeOH, reflux, and 1 h; (vii) DIPEA,
DMSO, rt, and 18 h; (viii) AcOH or EtOH, reflux, and 2 h; (ix) R2B(OH)2, Cu(OAc)2, pyridine, DCM, and 2 h; (x) Et2O, rt, 1 h, then NaOMe,
MeOH, rt, 18 h, then H2SO4, MeOH, reflux, and 48 h; (xi) PPh3, DIAD, THF, MeOH, rt, and 18 h; (xii) DIBAL, DCM, −78 °Crt, then MnO2,
DCM, rt, and 48 h; (xiii) AcOH, DCM, then NaBH(OAc)3, and 18 h; (xiv) R4B(OH)2, Cu(OAc)2, pyridine, DCM, rt, and 3−18 h.
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a humidified incubator, growing to mid-log to late-log phase,
each of the cultures was washed with fresh 7H9 and suspended
to an OD580 of 0.05 in 30 mL of 7H9 (with selection antibiotics
for the mutant but without atc to deplete the levels of MmpL3)
in a 75 cm2 tissue culture flask with a vented cap and was
incubated for further 14 days with a passage to OD580 = 0.05 in
30 mL of 7H9 at day 7. Bacteria were then washed once in fresh
medium and single-cell suspensions were prepared to a final
OD580 of 0.01 in 7H9. Compounds were solubilized in DMSO
and dispensed into 384-well plates using an HP D300e Digital
Dispenser as 11-point, 4-fold dilution series in triplicate. DMSO
at a final concentration of 1% was used as no-drug control. In
all, 50 μL of single-cell suspension was pipetted to each well and
cultures were incubated for 7−14 d at 37 °C in the same
conditions as mentioned above. Final OD580 values were
normalized to no-drug control.
M. tuberculosis Kill Kinetics. For replicating conditions,
late-log phase bacteria were exposed to compounds in 5 mL
medium under aerobic conditions in standing cultures over 21
days. For starvation conditions, bacteria were resuspended in
phosphate-buffered saline plus 0.05% tyloxapol for 14 days
before compound addition. Viable bacteria were measured by
plating serial dilutions and counting cfus after 4 weeks.
Intracellular Activity. THP-1 cells were propagated in
RPMI-1640 supplemented with 10% FBS, 2 mM glutagro, and
1 mM sodium pyruvate medium in a humidified atmosphere of
37 °C with 5% CO2. Cells were differentiated with 80 nM PMA
treatment overnight and infected with M. tuberculosis (H37Rv
LuxG13) at a multiplicity of infection of 1. Infected cells were
harvested with Accutase, 5 mM EDTA, washed twice with PBS,
seeded into 96-well plates at 4 × 104 cells per well, and
incubated for 24 h. Compounds were added as a 10-point three-
fold serial dilution (0.5% DMSO final concentration). Bacterial
viability was measured after 72 h. Growth inhibition curves
were fitted using the Levenberg−Marquardt algorithm. IC50
and IC90 were defined as the compound concentrations that
inhibited 50 or 90% of the intracellular growth, respectively.
THP-1 Cytotoxicity. THP-1 cells were propagated, differ-
entiated into macrophages, and harvested as described above
and seeded into 96-well plates at 4 × 104 cells per well for 24 h.
Compounds were added as a 10-point three-fold serial dilutions
(0.5% DMSO final concentration). Viability was measured after
72 h using CellTiter-Glo. Growth inhibition curves were fitted
using the Levenberg−Marquardt algorithm. IC50 was defined as
the compound concentration that reduced cell viability by 50%.
HepG2 Cytotoxicity. Compound dilution curves were
plated directly using a Labcyte Echo 550 acoustic dispenser
(125 nL) in 384-well white clear-bottomed plates (Greiner).
HepG2 cells (ECACC 85011430) were cultured in minimum
essential medium (supplemented with glutamax) with 10% FCS
and plated (25 μL) using a WellMate dispenser (1 × 105 per
well) and incubated for 72 h. Doxorubicin was used as a
positive control drug. Resazurin was then added to each well at
a final concentration of 45 μM, and fluorescence was measured
using PHERAstar LS (BMG Labtech) after 4 h of further
incubation (excitation of 528 nm and emission of 590 nm).
Raw data were normalized to controls and expressed as %
Scheme 2. General Synthetic Routes for the Synthesis of Compounds 22−30 and 35a
aReagents and conditions: (i) EtOH, AcOH, reflux, and 1−18 h; (ii) spiro[isochromane-1,4′-piperidine], AcOH, DCM, then NaBH(OAc)3, and
18 h; (iii) EtOH, H2O, 35 °C, and 18 h; (iv) SOCl2, pyridine, 50 °C, 2 h then ethanolamine, DCM, rt, 3 h, then SOCl2, rt, and 18 h; (v) NaH,
THF, 0 °C, and 3 h; (vi) DIBAL, DCM, −78 °Crt, then MnO2, DCM, rt, and 48 h; (vii) spiro[isochromane-1,4′-piperidine], AcOH, DCM, then
NaBH(OAc)3, 18 h; and (viii) 3 M HCl, 100 °C, and 18 h.
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growth. IC50 was defined as the compound concentration that
resulted in 50% inhibition.
Intrinsic Clearance (Cli) Experiments. Test compound
(0.5 μM) was incubated with female CD1 mouse liver
microsomes (Xenotech LLC) or pooled human liver micro-
somes (Life Technologies) at a final concentration of 0.5 mg/
mL 50 mM potassium phosphate buffer, pH 7.4, and the
reaction started with addition of excess NADPH (8 mg/mL 50
mM potassium phosphate buffer, pH 7.4). Immediately, at time
zero, then at 3, 6, 9, 15, and 30 min, an aliquot (50 μL) of the
incubation mixture was removed and mixed with acetonitrile
(100 μL) to stop the reaction. Internal standard was added to
all samples, the samples were centrifuged to sediment
precipitated protein, and the plates were then sealed prior to
ultra-performance liquid chromatography−mass spectrometry
(UPLC/MS/MS) analysis using a Quattro Premier XE (Waters
Corporation, USA). XLfit (IDBS, UK) was used to calculate the
exponential decay and consequently the rate constant (k) from
the ratio of peak area of test compound to internal standard at
each time point. The rate of intrinsic clearance (CLi) of each
test compound was then calculated using the following
calculation
k V
CLi (mL/min /g liver)
microsomal protein yield= × ×
where V (mL/mg protein) is the incubation volume/mg
protein added and microsomal protein yield is taken as 52.5 mg
protein/g liver. Verapamil (0.5 μM) was used as a positive
control to confirm acceptable assay performance.
Isoform-specific metabolism studies were performed as
mentioned above except that mouse liver microsomes were
replaced with incubation mixtures containing EasyCYP
bactosomes (50 pmol/mL, 0.5 mg/mL Cypex).
Aqueous Solubility. The aqueous solubility of the test
compounds was measured using laser nephelometry. Com-
pounds were subject to serial dilution from 10 to 0.5 mM in
DMSO. An aliquot was then mixed with Milli-Q water to obtain
an aqueous dilution plate with a final concentration range of
250−12 μM with a final DMSO concentration of 2.5%.
Triplicate aliquots were transferred to a flat-bottomed
polystyrene plate, which was immediately read on the
NEPHELOstar (BMG Lab Technologies). The amount of
laser scatter caused by insoluble particulates (relative
nephelometry units, RNU) was plotted against compound
concentration using a segmental regression fit, with the point of
inflection being quoted as the compound’s aqueous solubility
(μM).
Mouse Pharmacokinetics. The test compound was dosed
as a bolus solution intravenously or dosed orally by gavage to
female C57 black mice (n = 3/dose level). Blood samples were
collected from each mouse tail vein at predetermined time
points post-dose, mixed with two volumes of distilled water,
and stored frozen until UPLC/MS/MS analysis. Pharmacoki-
netic parameters were derived from the blood concentration
time curve using PK Solutions software v2.0 (Summit Research
Services, USA). All regulated procedures, at the University of
Dundee, on living animals were carried out under the authority
of a project license issued by the Home Office under the
Scheme 3. General Synthetic Routes for the Synthesis of Compounds 31−34a
aReagents and conditions: (i) POCl3, DMF, 100 °C, and 2 h; (ii) R3H, K2CO3, DMF, microwave, 120 °C, and 1 h; (iii) pTsOH, MeOH,
microwave, 120 °C, and 1 h; (iv) R3I, K2CO3, DMF, 0 °Crt, and 2 h; (v) DIBAL, DCM, −78 °Crt, then MnO2, DCM, rt, and 48 h; (vi)
AcOH, DCM, then NaBH(OAc)3, and 18 h; and (vii) N-formylsaccharin, Pd(OAc)2, Xantphos, KF, DMF, 80 °C, and 18 h then H2O.
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Animals (Scientific Procedures) Act 1986, as amended in 2012
(and in compliance with EU Directive EU/2010/63).
hERG Assays. These were performed as previously
described42,43 in brief: thallium flux high-throughput testing,
hERG functional activity was measured in an inducible hERG
T-RExTM-CHO Cell line (Thermo Fisher #K1237) using
thallium influx as a surrogate indicator of potassium ion channel
activity. Thallium enhances the fluorescent signal of BTC-AM
dye (Thermo Fisher #B6791). Cells were loaded with the dye
for 90 min in a low potassium buffer, dye removed, and
compound added to the cells in a high potassium buffer in a 6
pt. dose response. After 30 min of compound incubation,
channel activity was recorded upon addition of thallium buffer
using a Tetra plate reader. The slope of the kinetic read was
used to calculate channel activity. For QPatch testing, HEK-293
cells stably transfected with the hERG channel were tested in
either QPatch (Sophion) or PatchXpress (Molecular Devices),
automated planar patch-clamp systems. The cells were added to
each chamber, negative pressure was applied to obtain
intracellular access, and cells were exposed to either three or
four ascending concentrations of drug. hERG tail current was
measured as the difference in amplitude between a −50 mV
pre-pulse and the end of a five-second test pulse to −50 mV,
preceded by a depolarizing pulse (+20 mV). The hERG IC50
value was determined from tail current.
Murine Model of Acute TB Infection. All infections were
performed at Colorado State University in a certified ABSL3
facility in accordance with the guidelines of the Colorado State
University Institutional Animal Care and Use Committee. Six
to eight week old female specific pathogen-free BALB/c mice
were purchased from Charles River Laboratories (Wilmington,
MA). The mice were infected with M. tuberculosis H37Rv via a
low-dose aerosol exposure in a Glas-Col aerosol generation
device (Glas-Col Inc., Terre Haute, IN).44 Each treatment
group consisted of six mice. 29 was formulated in 1% CMC
(Sigma). 3 was formulated in 1% MC (Sigma). Rifampin was
prepared using a mortar and pestle in sterile water. The
treatment was started 7 days post-aerosol and continued for 12
consecutive days. Drugs were administered by oral gavage in a
0.2 mL volume at 300, 100, and 20 mg/kg for 29, 3, and
rifampicin, respectively. For endpoint analysis, mice were
euthanized 3 days following the end of treatment and lungs
were collected. The left lung lobe (1/3rd of the lung by weight)
was homogenized for enumeration of cfu by plating dilutions of
the organ homogenates on Middlebrook 7H11 medium
supplemented with 10% (v/v) OADC, 0.01 mg/mL of
cycloheximide, and 0.05 mg/mL of carbenicillin. The data
were expressed as mean log 10 cfu ± the standard error of the
mean for each group. Statistical analysis was done by one-way
analysis of variance with Dunnet’s post-test to control for
multiple comparisons (SigmaPlot, San Jose, CA). Values were
considered significant at the 95% confidence level.
General Chemistry Methods. Chemicals and solvents
were purchased from commercial vendors and used as received
unless otherwise stated. Dry solvents were purchased in Sure
Seal bottles stored over molecular sieves. Unless otherwise
stated herein, reactions have not been optimized. Analytical
thin-layer chromatography (TLC) was performed on precoated
TLC plates (Kieselgel 60 F254, BDH). Developed plates were
air-dried and analyzed under a UV lamp (UV 254/365 nm)
and/or KMnO4 was used for visualization. Flash chromatog-
raphy was performed using Combiflash Companion Rf
(Teledyne ISCO) and prepacked silica gel columns purchased
from Grace Davison Discovery Science or SiliCycle. Mass-
directed preparative HPLC separations were performed using a
Waters HPLC (2545 binary gradient pumps, 515 HPLC make-
up pump, and 2767 sample manager) connected to a Waters
2998 photodiode array and a Waters 3100 mass detector.
Preparative HPLC separations were performed with a Gilson
HPLC (321 pumps, 819 injection module, and 215 liquid
handler/injector) connected to a Gilson 155 UV/vis detector.
On both instruments, HPLC chromatographic separations were
conducted using Waters XBridge C18 columns, 19 mm × 100
mm, 5 μm particle size, using 0.1% ammonia in water (solvent
A) and acetonitrile (solvent B) as the mobile phase. 1H NMR
spectra were recorded on a Bruker ADVANCE II 500 or 400
spectrometer operating at 500 and 400 MHz (unless otherwise
stated) using CDCl3, DMSO-d6, or CD3OD solutions.
Chemical shifts (δ) are expressed in ppm recorded using the
residual solvent as the internal reference in all cases. Signal
splitting patterns are described as singlet (s), doublet (d),
triplet (t), multiplet (m), broadened (br), or a combination
thereof. Coupling constants (J) are quoted to the nearest 0.1
Hertz (Hz). Low-resolution electrospray mass spectra were
recorded on a Bruker Daltonics MicrOTOF mass spectrometer
run in the positive mode. High-resolution mass spectroscopy
(HRMS) was performed using a Bruker Daltonics MicroTof
mass spectrometer. LC−MS analysis and chromatographic
separation were conducted with either a Bruker Daltonics
MicroTOF mass spectrometer connected to an Agilent diode
array detector or a Thermo Dionex Ultimate 3000 RSLC
system with a diode array detector, the column used was a
Waters XBridge column (50 mm × 2.1 mm, 3.5 μm particle
size), and the compounds were eluted with a gradient of 5−95%
acetonitrile/water + 0.1% ammonia or with an Advion
Expression Mass Spectrometer connected to a Thermo Dionex
Ultimate 3000 HPLC with a diode array detector, the column
used was a Waters XBridge column (50 mm × 2.1 mm, 3.5 μm
particle size), or a Waters X-select column (30 mm × 2.1 mm,
2.5 μm particle size) with a gradient of 5−90% acetonitrile/
water + 0.1% formic acid. All final compounds showed chemical
purity of ≥95% as determined by the UV chromatogram (190−
450 nm) obtained by LC−MS analysis.
General Method 1. Respective spirocyclic amines (1
equiv) and aldehydes (1 equiv) were combined in DCM
(0.1−0.2 M), one drop of acetic acid was added, and the
mixtures were stirred at rt for 1 h. Sodium triacetoxyborohy-
dride (1.5−2 equiv) was added and the mixtures were stirred at
rt for 18 h. The mixtures were washed with NaHCO3 (saturated
solution) and the organics were concentrated in vacuo. The
crude materials were purified by preparative HPLC (XBridge
column, 0.1% NH4OH modifier) and the fractions were
concentrated in vacuo to afford the titled compounds.
General Method 2. Respective pyrazoles (1 equiv),
boronic acids (2 equiv), and copper acetate (1.5 equiv) were
combined in DCM (0.1 M) and pyridine (20 equiv) and stirred
at rt for 3−18 h. The solvents were removed in vacuo and the
crude products were purified by either flash chromatography
(0−100% EtOAc in heptane) or preparative HPLC (XBridge
column, 0.1% NH4OH modifier), and the fractions were
concentrated in vacuo to afford the titled compounds.
General Method 3a. Respective hydrazines (1 equiv) and
2,4-dioxo-butanoates (1 equiv) were dissolved in EtOH (0.15
M) and heated to reflux for 1−3 h. The solvent was removed in
vacuo and H2O was added. The products were extracted with
EtOAc and concentrated in vacuo, and the resulting crude
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products were purified by flash chromatography (5−50%
EtOAc in heptane) to afford the titled compounds.
General Method 3b. Respective hydrazines or hydrazine
hydrochlorides (1 equiv) and 2,4-dioxo-butanoates (1 equiv)
were dissolved in AcOH (0.7 M), and the reaction mixtures
were heated to reflux for 2 h and then allowed to cool to rt. The
solvent was removed in vacuo, and the residue was partitioned
between DCM and 1 M NaOH and then passed through a
hydrophobic frit. The crude materials were purified by flash
chromatography (0−100% EtOAc in heptane) to afford the
titled compounds.
General Method 4. Oxazolines (1 equiv) were dissolved in
3 M HCl (30 equiv) and heated to 100 °C for 18 h and then
allowed to cool to rt. The reaction mixtures were neutralized
with NaHCO3 (saturated solution) and extracted with DCM.
The organics were separated, dried through a hydrophobic frit,
and concentrated in vacuo to afford the titled compounds.
General Method 5. Bromides (1 equiv), aldehydes (1.2
equiv), Pd(OAc)2 (3 mol %), Xantphos (4.5 mol %), and KF
(2.5 equiv) were combined in DMF (0.12 M) in sealed tubes.
The reaction mixtures were heated to 80 °C for 18 h. The
reactions were quenched with H2O and stirred at rt for 10 min.
DCM was added and the mixtures were filtered through Celite
and washed with further DCM. The combined organics were
concentrated in vacuo and purified by preparative HPLC
(XBridge column, 0.1% NH4OH modifier), and the fractions
were concentrated in vacuo to afford the titled compounds.
General Method 6a. Esters (1 equiv) were dissolved in
DCM (0.2−0.4 M) and cooled to −78 °C under N2. DIBAL
(2.5 equiv, 1 M in DCM) was added dropwise over 20 min, and
the reactions were stirred for 1 h at −78 °C. The reaction
mixtures were quenched carefully with H2O and MeOH (1:1,
10 mL) and allowed to warm to rt. DCM was added and the
mixtures were passed through hydrophobic frits. The organics
were concentrated in vacuo, and the crude products were
purified by flash chromatography (0−100% EtOAc in heptane)
to afford the titled compounds.
General Method 6b. Esters (1 equiv) were dissolved in
DCM (0.2−0.4 M) and cooled to −78 °C under N2. DIBAL
(2.5 equiv, 1 M in DCM) was added dropwise over 20 min and
the reactions were stirred for 1 h at −78 °C. The reaction
mixtures were quenched carefully with H2O and MeOH (1:1,
10 mL) and allowed to warm to rt. DCM was added and the
mixtures were passed through hydrophobic frits. The organics
were concentrated in vacuo to afford the alcohols. The residues
were redissolved in DCM and MnO2 (10 equiv) was added.
The reaction mixtures were stirred at rt for 18 h, then filtered
through Celite cartridges, and washed well with DCM and




pyran] (1) (Scheme 1). 5-Methyl-1-phenyl-1H-pyrazole-3-
carbaldehyde (70). Ethyl 5-methyl-1-phenyl-1H-pyrazole-3-
carboxylate (2.00 g, 8.69 mmol) and DIBAL (1 M in DCM)
(21.72 mL, 21.72 mmol) were combined in DCM (20 mL)
according to General Method 6a. Work-up and purification
afforded the title compound as a pale yellow oil (678 mg, 41%).
LCMS (ESI) m/z: 189 (M + H)+. 1H NMR (500 MHz,
CDCl3): δ 7.50−7.42 (m, 4H), 7.42−7.37 (m, 1H), 6.22 (s,
1H), 4.72 (d, J = 5.9 Hz, 2H), 2.34 (s, 3H), 2.10 (br s, 1H).
1-((5-Methyl-1-phenyl-1H-pyrazol-3-yl)methyl)-4′,5′-
dihydrospiro[piperidine-4,7′-thieno[2,3-c]pyran] (1). 5-Meth-
yl-1-phenyl-pyrazole-3-carbaldehyde (70) (40 mg, 0.21 mmol),
spiro[4,5-dihydrothieno[2,3-c]pyran-7,4′-piperidine] (43 mg,
0.20 mmol), and sodium triacetoxyborohydride (91 mg, 0.43
mmol) were combined in DCM (4 mL) according to General
Method 1. Work-up and purification afforded the title
compound (30 mg, 35%). HRMS (ESI) m/z: calcd for
C22H26N3OS [M + H
+], 380.1791; found, 380.1794. 1H
NMR (500 MHz, CDCl3): δ 7.47 (d, J = 4.4 Hz, 4H), 7.39−
7.35 (m, 1H), 7.15 (d, J = 5.0 Hz, 1H), 6.78 (d, J = 5.0 Hz, 1H),
6.24 (s, 1H), 3.94 (dd, J = 5.5, 5.5 Hz, 2H), 3.67 (s, 2H), 2.88
(d, J = 11.6 Hz, 2H), 2.72 (dd, J = 5.5, 5.5 Hz, 2H), 2.58−2.51
(m, 2H), 2.36 (s, 3H), 2.07−2.03 (m, 4H).
Synthesis of 1′-((1-Methyl-5-phenyl-1H-pyrazol-3-yl)-
methyl)spiro[isochromane-1,4′-piperidine] (2) (Scheme 1).
Spiro[isochromane-1,4′-piperidine] (98 mg, 0.48 mmol), 3-
(chloromethyl)-1-methyl-5-phenyl-1H-pyrazole (54) (50 mg,
0.24 mmol), and diisopropylethylamine (93 mg, 0.73 mmol)
were combined in DMSO (1 mL) and stirred at rt for 18 h.
Water (0.3 mL) was added, the mixture was purified by
preparative HPLC (XBridge column, 0.1% NH4OH modifier),
and the fractions were concentrated in vacuo to afford the title
compound (40 mg, 42%). HRMS (ESI) m/z: calcd for
C24H28N3O [M + H
+], 374.2232; found, 374.2180. 1H NMR
(500 MHz, CDCl3): δ 7.46−7.40 (5H, m), 7.22−7.12 (3H, m),
7.08 (1H, d, J = 7.3 Hz), 6.31 (1H, s), 3.91 (2H, t, J = 5.5 Hz),
3.88 (3H, s), 3.64 (2H, s), 2.90−2.87 (2H, m), 2.83 (2H, t, J =





[piper idine-4,4 ′ - thieno[3,2-c]pyran] (48 ) . 1-[(4-
Methoxyphenyl)methyl]piperidin-4-one (1.71 g, 7.80 mmol)
and 2-(thiophen-2-yl)ethan-1-ol (1.00 g, 7.80 mmol) were
mixed in toluene (70 mL) and methanesulfonic acid (1 mL,
15.60 mmol) was added. The reaction mixture was heated to
130 °C in Dean−Stark apparatus for 18 h. The reaction mixture
was allowed to cool to rt and toluene was removed in vacuo.
The residue was dissolved in MeOH and loaded onto a 20 g
SCX cartridge, eluting with MeOH and 3 M NH3/MeOH. The
crude material was purified further by flash chromatography
(0−8% MeOH in DCM with NH3 modifier) to afford the title
compound (940 mg, 35%). 1H NMR (500 MHz, CDCl3): δ
6.73 (d, J = 2.7 Hz, 3H), 6.55 (d, J = 1.7 Hz, 1H), 6.35 (dd, J =
10.8, 10.8 Hz, 2H), 6.31−6.28 (m, 1H), 4.77 (d, J = 2.4 Hz,
1H), 3.43−3.38 (m, 2H), 3.29 (d, J = 2.3 Hz, 3H), 2.98 (s, 2H),
2.30 (dd, J = 5.0, 5.0 Hz, 2H), 2.19−2.16 (m, 2H), 1.44 (dd, J =
12.1, 12.1 Hz, 2H), 1.32 (d, J = 12.8 Hz, 2H).
6′,7′-Dihydro-1,2-spiro[piperidine-4,4′-thieno[3,2-c]-
pyran] (49). 1′-[(4-Methoxyphenyl)methyl]spiro[6,7-
dihydrothieno[3,2-c]pyran-4,4′-piperidine (48) (940 mg, 2.85
mmol) was dissolved in DCM (15 mL) under N2 and cooled to
0 °C. 1-Chloroethyl carbonochloridate (530 mg, 3.71 mmol) in
DCM (3 mL) was then added dropwise, and the reaction
mixture was stirred at 0 °C for 30 min and then allowed to
warm up to rt. The volatiles were removed in vacuo, and the
residue was dissolved in MeOH (15 mL) and heated to reflux
for 1 h. After cooling to rt, the reaction mixture was passed
through a 20 g SCX cartridge, eluting the amine with 3 MNH3/
MeOH to afford the title compound as a pale orange gum,
which solidified on standing at rt (480 mg, 76%). 1H NMR
(400 MHz, CDCl3): δ 7.10 (d, J = 5.2 Hz, 1H), 6.83 (d, J = 5.2
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Hz, 1H), 3.97 (dd, J = 5.4, 5.4 Hz, 2H), 3.11−3.03 (m, 2H),
2.95−2.83 (m, 4H), 1.88−1.83 (m, 4H).
1′-[[4-[4-(Trifluoromethoxy)phenoxy]phenyl]methyl]-
spiro[6,7-dihydrothieno[3,2-c]pyran-4,4′-piperidine] (3). 4-
(Trifluoromethoxy)phenol (1.0 g, 5.61 mmol) and 4-
fluorobenzaldehyde (697 mg, 5.61 mmol) were mixed in
DMF (10 mL) and K2CO3 (931 mg, 6.74 mmol) was added.
The reaction mixture was heated at 140 °C for 8 h and then
allowed to cool to rt. H2O was added and the product was
extracted with Et2O. The combined organics were washed with
brine, dried (MgSO4), and concentrated in vacuo to afford 4-(4-
(trifluoromethoxy)phenoxy)benzaldehyde as a yellow oil (1.40
g, 80%). 1H NMR (500 MHz, CDCl3): δ 9.98 (s, 1H), 7.90 (d,
2H), 7.30 (m, 2H), 7.11 (m, 4H). 4-[4-(Trifluoromethoxy)-
phenoxy]benzaldehyde (60 mg, 0.21 mmol), 6′,7′-dihydro-1,2-
spiro[piperidine-4,4′-thieno[3,2-c]pyran] (49) (45 mg, 0.21
mmol), and sodium triacetoxyborohydride (90 mg, 0.43 mmol)
were combined in DCM (3 mL) according to General Method
1. Work-up and purification afforded the title compound (52
mg, 51%). LCMS (ESI) m/z: 476 [M + H]+. HRMS (ESI) m/
z: calcd for C25H25F3NO3S [M + H
+], 476.1507; found,
476.1489. 1H NMR (500 MHz, CDCl3): δ 7.34 (d, J = 8.6 Hz,
2H), 7.19−7.15 (m, 2H), 7.07 (d, J = 5.2 Hz, 1H), 7.02−6.96
(m, 4H), 6.81 (d, J = 5.2 Hz, 1H), 3.93 (t, J = 5.4 Hz, 2H), 3.54
(s, 1H), 2.83 (t, J = 5.4 Hz, 2H), 2.75−2.70 (m, 2H), 2.40 (td, J
= 12.1, 2.6 Hz, 2H), 1.97 (td, J = 13.4, 4.4 Hz, 2H), 1.89−1.83
(m, 2H).
Synthesis of 1′-((5-Methyl-1-phenyl-1H-pyrazol-3-yl)-
methyl)spiro[isochromane-1,4′-piperidine] (4) (Scheme 1).
Spiro[isochromane-1,4′-piperidine] (200 mg, 0.98 mmol), 5-
methyl-1-phenyl-1H-pyrazole-3-carbaldehyde (70) (183 mg,
0.98 mmol), and sodium triacetoxyborohydride (417 mg, 1.97
mmol) were combined in DCM (4 mL) according to General
Method 1. Work-up and purification afforded the title
compound (244 mg, 65%). LCMS (ESI) m/z: 374 (M +
H)+. HRMS (ESI) m/z: calcd for C24H28N3O [M + H
+],
374.2227; found, 374.2235. 1H NMR (400 MHz, CDCl3): δ
7.47−7.43 (m, 4H), 7.38−7.32 (m, 1H), 7.23−7.11 (m, 3H),
7.10−7.06 (m, 1H), 6.22 (s, 1H), 3.90 (t, J = 5.6 Hz, 2H), 3.66
(s, 1H), 2.89−2.80 (m, 4H), 2.52 (t, J = 12.1 Hz, 2H), 2.34 (d, J
= 0.7 Hz, 3H), 2.08 (td, J = 13.2, 4.5 Hz, 2H), 1.95−1.87 (m,
2H).
Synthesis of 9-((5-Methyl-1-phenyl-1H-pyrazol-3-yl)-
methyl)-1-oxa-9-azaspiro[5.5]undecane (5) (Scheme 1). 1-
Oxa-9-azaspiro[5.5]undecane hydrochloride (50 mg, 0.26
mmol), 5-methyl-1-phenyl-1H-pyrazole-3-carbaldehyde (70)
(51 mg, 0.27 mmol), and sodium triacetoxyborohydride (110
mg, 0.52 mmol) were combined in DCM (2 mL) according to
General Method 1. Work-up and purification afforded the title
compound. LCMS (ESI) m/z: 326 (M + H)+. 1H NMR (500
MHz, CDCl3): δ 7.45−7.42 (m, 3H), 7.36−7.32 (m, 1H), 6.17
(s, 1H), 3.63 (t, J = 5.2 Hz, 2H), 3.58 (s, 2H), 2.63 (m, 2H),
2.44 (m, 2H), 2.32 (d, J = 0.5 Hz, 3H), 1.89 (d, J = 13.4, 2H),





fluorophenyl)ethan-1-ol (6.48 g, 29.58 mmol) was dissolved
in THF (10 mL) and cooled to −78 °C. 2.5 M n-BuLi solution
(23.67 mL, 59.17 mmol) was added dropwise and continuously
stirred at −78 °C for 1 h. tert-Butyl 4-oxopiperidine-1-
carboxylate (5.89 g, 29.58 mmol) was dissolved in THF (10
mL), and the solution was added dropwise to the reaction
mixture. The mixture was continuously stirred at−78 °C for 1 h
before allowing to warm slowly to rt over 18 h. The reaction was
quenched with NH4Cl (saturated solution), EtOAc was added,
and the organic layer was separated and dried (hydrophobic
frit). The crude material was purified by flash chromatography
(20−50% EtOAc in heptane) to afford the title compound.
LCMS (ESI) m/z: 240 (M-CO2
tBu + H)+. 1H NMR (500
MHz, CDCl3): δ 7.24 (dd, J = 8.9, 5.9 Hz, 1H), 6.89 (dd, J =
10.0, 2.8 Hz, 1H), 6.84 (ddd, J = 8.9, 7.8, 2.8 Hz, 1H), 3.94 (br
s, 2H), 3.89−3.84 (m, 2H), 3.31−3.19 (br m, 4H), 1.94−1.86
(m, 2H), 1.82 (d, J = 12.7 Hz, 2H), 1.80−1.75 (m, 2H), 1.44 (s,
9H).
tert-Butyl 6-Fluorospiro[isochromane-1,4′-piperidine]-1′-
carboxylate (44). tert-Butyl 4-[4-fluoro-2-(2-hydroxyethyl)-
phenyl]-4-hydroxy-piperidine-1-carboxylate (40) (3.48 g,
10.25 mmol) and triethylamine (2.86 mL, 20.51 mmol) were
combined in DCM (15 mL) and cooled to 0 °C.
Methanesulfonyl chloride (0.79 mL, 10.25 mmol) was added
dropwise and the reaction was allowed to warm to rt and then
heated to reflux for 90 min. The reaction was then allowed to
cool to rt and washed with H2O. The organics were separated
and concentrated in vacuo. The crude material was purified by
flash chromatography (10−50% EtOAc in heptane) to afford
the title compound (1.96 g, 59%). 1H NMR (400 MHz,
CDCl3): δ 7.03, (dd, J = 8.7, 5.5 Hz, 1H), 6.88 (td, J = 8.5, 2.7
Hz, 1H), 6.79 (dd, J = 9.3, 2.7 Hz, 1H), 3.99 (br s, 2H), 3.89 (t,
J = 5.5 Hz, 2H), 3.13 (br s, 2H), 2.81 (t, J = 5.5 Hz, 2H), 1.90−
1.76 (m, 4H), 1.49 (s, 9H).
6-Fluorospiro[isochromane-1,4′-piperidine] (50). tert-
Butyl 6-fluorospiro[isochromane-1,4′-piperidine]-1′-carboxy-
late (44) (1.96 g, 6.10 mmol) was dissolved in DCM (5 mL)
and trifluoroacetic acid (4.17 mL, 54.50 mmol) was added. The
reaction was stirred at rt for 18 h. The reaction mixture was
diluted with MeOH and loaded onto an SCX cartridge eluting
with MeOH and then 3 M NH3 in MeOH to elute the product.
The solvents were removed in vacuo to afford the title
compound (1.21 g, 90%). LCMS (ESI) m/z: 222 (M + H)+.
1H NMR (400 MHz, CDCl3): δ 7.13 (dd, J = 8.7, 5.7 Hz, 1H),
6.88 (td, J = 8.7, 2.7 Hz, 1H), 6.78 (dd, J = 9.3, 2.7 Hz, 1H),
3.89 (t, J = 5.5 Hz, 2H), 3.11−3.02 (m, 2H), 2.93−2.86 (m,
2H), 2.81 (t, J = 5.5 Hz, 2H), 1.89−1.81 (m, 4H).
6-Fluoro-1′-((5-methyl-1-phenyl-1H-pyrazol-3-yl)methyl)-
spiro[isochromane-1,4′-piperidine] (6). 6-Fluorospiro-
[isochromane-1,4′-piperidine] (50) (40 mg, 0.18 mmol), 5-
methyl-1-phenyl-1H-pyrazole-3-carbaldehyde (70) (34 mg,
0.18 mmol), and sodium triacetoxyborohydride (77 mg, 0.36
mmol) were combined in DCM (2 mL) according to General
Method 1. Work-up and purification afforded the title
compound. LCMS (ESI) m/z: 392 (M + H)+. HRMS (ESI)
m/z: calcd for C24H27FN3O [M + H
+], 392.2138; found,
392.2080. 1H NMR (500 MHz, CDCl3): δ 7.46−7.43 (m, 4H),
7.38−7.32 (m, 1H), 7.15 (dd, J1 = 8.7 Hz, J2 = 5.6 Hz, 1H), 6.87
(td, J1 = 8.6 Hz, J2 = 2.7 Hz, 1H), 6.77 (dd, J1 = 9.3 Hz, J2 = 2.7
Hz, 1H), 6.21 (s, 1H), 3.87 (t, J = 5.5 Hz, 2H), 3.65 (s, 2H),
2.85 (m, 2H), 2.80 (t, J = 5.5 Hz, 2H), 2.51 (t, J = 13.1 Hz, 2H),




1). 7-Fluorospiro[isochromane-1,4′-piperidine] (40 mg, 0.18
mmol), 5-methyl-1-phenyl-1H-pyrazole-3-carbaldehyde (70)
(34 mg, 0.18 mmol), and sodium triacetoxyborohydride (77
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mg, 0.36 mmol) were combined in DCM (2 mL) according to
General Method 1. Work-up and purification afforded the title
compound. LCMS (ESI) m/z: 392 (M + H)+. 1H NMR (500
MHz, CDCl3): δ 7.48−7.42 (m, 4H), 7.38−7.32 (m, 1H),
7.05−7.00 (m, 1H), 6.91 (dd, J1 = 10.3 Hz, J2 = 2.6 Hz, 1H),
6.83 (td, J1 = 8.4 Hz, J2 = 2.6 Hz, 1H), 6.22 (s, 1H), 3.87 (t, J =
5.5 Hz, 2H), 3.64 (s, 2H), 2.85 (m, 2H), 2.77 (t, J = 5.5 Hz,
2H), 2.55−2.46 (m, 2H), 2.43 (d, J = 0.6 Hz, 3H), 2.07−1.97
(m, 2H), 1.93−1.86 (m, 2H).
Synthesis of 6,7-Difluoro-1′-((5-methyl-1-phenyl-1H-pyr-
azol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (8)
(Scheme 1). 2-(2-Bromo-4,5-difluoro-phenyl)ethanol (38).
2-(2-Bromo-4,5-difluoro-phenyl)acetic acid (36) (1.04 g, 4.14
mmol) was dissolved in THF (20 mL) and BH3.THF (1 M
solution, 10.8 mL, 10.8 mmol) was added dropwise. The
resultant solution was heated to 100 °C for 1 h. The solution
was then allowed to cool to rt and H2O (15 mL) was carefully
added until effervescence is ceased, followed by K2CO3
portionwise until effervescence is ceased. Et2O (20 mL) was
then added and the layers were separated. The organic liquors
were washed with NaHCO3 (saturated aqueous solution) and
brine, dried (MgSO4), separated via a hydrophobic frit and then
concentrated in vacuo to afford the crude product. Purification
by flash chromatography (10−20% EtOAc in heptane) afforded
the title compound. 1H NMR (400 MHz, CDCl3): δ 7.38 (dd,
J1 = 11.9 Hz, J2 = 9.7 Hz, 1H), 7.14 (dd, J1 = 10.9 Hz, J2 = 8.2
Hz, 1H), 3.89−3.82 (m, 2H), 2.95 (t, J = 6.5 Hz, 2H), 1.62 (t, J
= 5.4 Hz, 1H).
tert-Butyl 4-[4,5-Difluoro-2-(2-hydroxyethyl)phenyl]-4-hy-
droxy-piperidine-1-carboxylate (41). 2-(2-Bromo-4,5-di-
fluoro-phenyl)ethanol (38) (954 mg, 4.02 mmol) was dissolved
in THF (15 mL) and cooled to −78 °C. n-BuLi (2.5 M
solution, 3.22 mL, 8.05 mmol) was added dropwise and the
mixture was stirred at −78 °C for 1 h. tert-Butyl 4-
oxopiperidine-1-carboxylate (0.80 g, 4.02 mmol) was dissolved
in THF (10 mL), and the solution was added dropwise to the
reaction mixture. The mixture was continuously stirred at −78
°C for 1 h before being allowed to warm slowly to rt over 18 h.
The reaction mixture was then quenched with saturated
aqueous ammonium chloride (10 mL), EtOAc (20 mL) was
added, and then the organic layer was separated via a
hydrophobic frit, dried (MgSO4), and concentrated in vacuo
to afford the crude product. This product was purified by flash
chromatography (20−50% EtOAc in heptane) to afford the
title compound. LCMS (ESI) m/z: 358 (M + H)+. 1H NMR
(400 MHz, CDCl3): δ 7.11 (dd, J1 = 12.6 Hz, J2 = 8.5 Hz, 1H),
7.01 (dd, J1 = 11.2 Hz, J2 = 8.4 Hz, 1H), 4.16−3.89 (m, 4H),
3.48 (d, J = 5.2 Hz, 2H), 3.34−3.18 (m, 4H), 1.94−1.77 (m,
4H), 1.47 (s, 9H).
tert-Butyl 6,7-Difluorospiro[isochromane-1,4′-piperidine]-
1′-carboxylate (45). tert-Butyl 4-[4,5-difluoro-2-(2-
hydroxyethyl)phenyl]-4-hydroxy-piperidine-1-carboxylate
(41) (185 mg, 0.52 mmol) was dissolved in DCM (6 mL) and
Et3N (154 μL, 1.11 mmol) was added. The reaction mixture
was cooled to 0 °C and then methanesulfonyl chloride (43 μL,
0.55 mmol) was added dropwise. Once the addition was
complete, the reaction was allowed to warm to rt for 45 min
before heating to reflux for 90 min. The reaction mixture was
allowed to cool to rt and washed with H2O. The volatiles were
removed in vacuo to afford a pale yellow oil. This product was
purified by flash chromatography (10−50% EtOAc in heptane)
to afford the title compound. 1H NMR (500 MHz, CDCl3): δ
6.92−6.82 (m, 2H), 4.17−3.80 (m, 4H), 3.28−2.94 (m, 2H),
2.82−2.68 (m, 2H), 1.93−1.70 (m, 4H), 1.49 (s, 9H).
6,7-Difluorospiro[isochromane-1,4′-piperidine] (51). tert-
Butyl 6,7-difluorospiro[isochromane-1,4′-piperidine]-1′-car-
boxylate (45) (106 mg, 0.31 mmol) was dissolved in DCM
(2 mL) and to the solution was added TFA (24 μL, 0.31 mmol)
at rt for 18 h and then concentrated in vacuo. The residue was
loaded onto a 1 g SCX cartridge using MeOH, eluting with 3 M
NH3 in MeOH. The solvents were removed in vacuo to afford
the title compound. LCMS (ESI) m/z: 240 (M + H)+. 1H
NMR (500 MHz, CDCl3): δ 6.96 (dd, J1 = 11.6 Hz, J2 = 7.9 Hz,
1H), 6.86 (dd, J1 = 10.7 Hz, J2 = 8.0 Hz, 1H), 3.86 (t, J = 5.5
Hz, 2H), 3.10−3.00 (m, 2H), 2.96−2.87 (m, 2H), 2.80−2.60
(m, 3H), 1.91−1.75 (m, 4H).
6,7-Difluoro-1′-((5-methyl-1-phenyl-1H-pyrazol-3-yl)-
methyl)spiro[isochromane-1,4′-piperidine] (8). 6,7-
Difluorospiro[isochromane-1,4′-piperidine] (51) (27 mg,
0.11 mmol), 5-methyl-1-phenyl-1H-pyrazole-3-carbaldehyde
(70) (21 mg, 0.11 mmol), and sodium triacetoxyborohydride
(48 mg, 0.23 mmol) were combined in DCM (4 mL) according
to General Method 1. Work-up and purification afforded the
title compound. LCMS (ESI) m/z: 410 (M + H)+. 1H NMR
(400 MHz, CDCl3): δ 7.50−7.45 (m, 4H), 7.41−7.35 (m, 1H),
7.06−6.97 (m, 1H), 6.99−6.84 (m, 1H), 6.23 (s, 1H), 3.89 (t, J
= 5.6 Hz, 2H), 3.66 (s, 2H), 2.87 (m, 2H), 2.77 (t, J = 5.4 Hz,
2H), 2.51 (td, J1 = 11.9 Hz, J2 = 2.8 Hz, 2H), 2.36 (d, J = 0.5
Hz, 3H), 2.06−1.95 (m, 2H), 1.94−1.86 (m, 2H).
Synthesis of 1′-((5-Methyl-1-phenyl-1H-pyrazol-3-yl)-
methyl)-6-(Trifluoromethyl)spiro[isochromane-1,4′-piperi-
dine] (9) (Scheme 1). 2-[2-Bromo-5-(trifluoromethyl)phenyl]-
ethanol (39). 2-[2-Bromo-5-(trifluoromethyl)phenyl]acetic
acid (37) (850 mg, 3.00 mmol) was dissolved in THF (10
mL) and BH3.THF (1 M solution, 3.90 mL, 3.90 mmol) was
added dropwise. The resultant solution was heated to 100 °C
for 1 h. The solution was then allowed to cool to rt and H2O
(15 mL) was carefully added until effervescence is ceased,
followed by K2CO3 portionwise until effervescence is ceased.
Et2O (20 mL) was then added and the layers were separated.
The organics were washed with NaHCO3 (saturated aqueous
solution) and brine, dried (MgSO4), separated via a hydro-
phobic frit, and then concentrated in vacuo to afford the crude
product. This product was purified by flash chromatography
(10−20% EtOAc in heptane) to afford the title compound. 1H
NMR (500 MHz, CDCl3): δ 7.70−7.66 (m, 1H), 7.56−7.52
(m, 1H), 7.37−7.32 (m, 1H), 3.91 (t, J = 6.6 Hz, 2H), 3.08 (t, J
= 6.6 Hz, 2H).
ter t -Buty l 4 -Hydroxy-4- [2 - (2-hydroxyethy l ) -4-
(trifluoromethyl)phenyl]piperidine-1-carboxylate (42). 2-[2-
Bromo-5-(trifluoromethyl)phenyl]ethanol (39) (780 mg, 2.90
mmol) was dissolved in THF (15 mL) and cooled to −78 °C.
n-BuLi (2.5 M solution, 2.32 mL, 5.80 mmol) was added
dropwise and the mixture was stirred at −78 °C for 1 h. tert-
Butyl 4-oxopiperidine-1-carboxylate (578 mg, 2.90 mmol)
dissolved in THF (10 mL) and the solution was added
dropwise to the reaction mixture. The mixture was continu-
ously stirred at −78 °C for 1 h before being allowed to warm
slowly to rt over 18 h. The reaction mixture was then quenched
with saturated aqueous ammonium chloride (10 mL). EtOAc
(20 mL) was added and the organic layer was separated via a
hydrophobic frit, dried (MgSO4), and concentrated in vacuo to
afford the crude product. This product was purified by flash
chromatography (20−50% EtOAc in heptane) to afford the
title compound. 1H NMR (400 MHz, CDCl3): δ 7.46−7.38 (m,
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3H), 4.31 (br s, 1H), 4.10−3.88 (m, 3H), 3.52−3.19 (m, 6H),
2.03−1.77 (m, 4H), 1.47 (s, 9H).
tert-Butyl 6-(Trifluoromethyl)spiro[isochromane-1,4′-pi-
peridine]-1′-carboxylate (46). tert-Butyl 4-hydroxy-4-[2-(2-
hydroxyethyl)-4-(trifluoromethyl)phenyl]piperidine-1-carbox-
ylate (42) (342 mg, 0.88 mmol) was dissolved in DCM (6 mL)
and Et3N (245 μL, 1.76 mmol) was added. The reaction
mixture was cooled to 0 °C and then methanesulfonyl chloride
(68 μL, 0.88 mmol) was added dropwise. Once the addition
was complete, the reaction was allowed to warm to rt for 45 min
before heating to reflux for 90 min. The reaction mixture was
allowed to cool to rt and washed with H2O. The organics were
concentrated in vacuo to afford a pale yellow oil. This product
was purified by flash chromatography (10−50% EtOAc in
heptane) to afford the title compound. LCMS (ESI) m/z: 372
(M + H)+. 1H NMR (500 MHz, CDCl3): δ 7.43 (d, J = 8.2 Hz,
1H), 7.36 (s, 1H), 7.19 (d, J = 8.2 Hz, 1H), 4.17−3.87 (m, 4H),




peridine]-1′-carboxylate (46) (169 mg, 0.46 mmol) was
dissolved in DCM (2 mL) and to the solution was added
TFA (0.5 mL, 6.53 mmol) at rt for 18 h and then concentrated
in vacuo. The residue was loaded onto a 1 g SCX cartridge using
MeOH, eluting with 3 M NH3 in MeOH. The solvents were
removed in vacuo to afford the title compound. LCMS (ESI)
m/z: 272 (M + H)+. 1H NMR (500 MHz, CDCl3): δ 7.45−
7.24 (m, 3H), 3.91−3.85 (m, 2H), 3.79 (br s, 1H), 3.12−3.02





(31 mg, 0.11 mmol), 5-methyl-1-phenyl-1H-pyrazole-3-carbal-
dehyde (70) (21 mg, 0.11 mmol), and sodium triacetoxybor-
ohydride (48 mg, 0.23 mmol) were combined in DCM (4 mL)
according to General Method 1. Work-up and purification
afforded the title compound. LCMS (ESI) m/z: 442 (M + H)+.
1H NMR (400 MHz, CDCl3): δ 7.50−7.42 (m, 5H), 7.40−7.32
(m, 3H), 6.24 (s, 1H), 3.93 (t, J = 5.5 Hz, 2H), 3.68 (s, 2H),
2.94−2.85 (m, 2H), 2.60−2.49 (m, 2H), 2.36 (d, J = 0.7 Hz,
3H), 2.16−2.04 (m, 2H), 1.96−1.88 (m, 2H).
Synthesis of 7,8-Difluoro-1′-((5-methyl-1-phenyl-1H-pyr-
azol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (10)
(Scheme 1). tert-Butyl 4-[4,5-Difluoro-2-(2-hydroxyethyl)-
phenyl]-4-hydroxy-piperidine-1-carboxylate (43). 2-(2-
Bromo-4,5-difluoro-phenyl)ethanol (954 mg, 4.02 mmol) was
dissolved in THF (15 mL) and cooled to −78 °C. n-BuLi (2.5
M solution, 3.22 mL, 8.05 mmol) was added dropwise and the
mixture was stirred at −78 °C for 1 h. tert-Butyl 4-
oxopiperidine-1-carboxylate (0.80 g, 4.02 mmol) dissolved in
THF (10 mL) and the solution was added dropwise to the
reaction mixture. The mixture was continuously stirred at −78
°C for 1 h before being allowed to warm slowly to rt over 18 h.
The reaction mixture was then quenched with saturated
aqueous ammonium chloride (10 mL). EtOAc (20 mL) was
added and the organic layer was separated via a hydrophobic
frit, dried (MgSO4), and concentrated in vacuo to afford the
crude product. This product was purified by flash chromatog-
raphy (20−50% EtOAc in heptane) to afford the title
compound. LCMS (ESI) m/z: 358 (M + H)+. 1H NMR (400
MHz, CDCl3): δ 7.02−6.93 (m, 1H), 6.87−6.80 (m, 1H),
4.00−3.75 (m, 4H), 3.61−3.04 (m, 6H), 2.47−2.31 (m, 2H),
1.68−1.56 (m, 2H), 1.46 (s, 9H).
tert-Butyl 7,8-Difluorospiro[isochromane-1,4′-piperidine]-
1′-carboxylate (47). tert-Butyl 4-[4,5-difluoro-2-(2-
hydroxyethyl)phenyl]-4-hydroxy-piperidine-1-carboxylate
(43) (198 mg, 0.55 mmol) was dissolved in DCM (6 mL) and
Et3N (155 μL, 1.11 mmol) was added. The reaction mixture
was cooled to 0 °C and then methanesulfonyl chloride (43 μL,
0.55 mmol) was added dropwise. Once the addition was
complete, the reaction was allowed to warm to rt for 45 min
before heating to reflux for 90 min. The reaction mixture was
allowed to cool to room temperature (rt) and washed with
water. The organic liquors were concentrated in vacuo to afford
a pale yellow oil. This product was purified by flash
chromatography (10−50% EtOAc in heptane) to afford the
title compound. 1H NMR (500 MHz, CDCl3): δ 7.02−6.95 (m,
1H), 6.88−6.82 (m, 1H), 4.15−3.83 (m, 4H), 3.31−3.01 (m,
2H), 2.84−2.72 (m, 2H), 2.32−2.22 (m, 2H), 1.89−1.67 (m,
2H), 1.49 (s, 9H).
7,8-Difluorospiro[isochromane-1,4′-piperidine] (53). tert-
Butyl 7,8-difluorospiro[isochromane-1,4′-piperidine]-1′-car-
boxylate (47) (81 mg, 0.24 mmol) was dissolved in DCM (2
mL) and to the solution was added TFA (18 μL, 0.24 mmol) at
rt for 18 h and then concentrated in vacuo. The residue was
loaded onto a 1 g SCX cartridge using MeOH, eluting with 3 M
NH3 in MeOH. The solvents were removed in vacuo to afford
the title compound. LCMS (ESI) m/z: 240 (M + H)+. 1H
NMR (500 MHz, CDCl3): δ 7.01−6.92 (m, 1H), 6.86−6.79
(m, 1H), 3.86 (t, J = 5.5 Hz, 2H), 3.40 (br s, 1H), 3.17−3.05
(m, 2H), 3.01−2.90 (m, 2H), 2.80−2.71 (m, 2H), 2.35−2.22
(m, 2H), 1.85−1.76 (m, 2H).
7,8-Difluoro-1′-((5-methyl-1-phenyl-1H-pyrazol-3-yl)-
methyl)spiro[isochromane-1,4′-piperidine] (10). 7,8-
Difluorospiro[isochromane-1,4′-piperidine] (53) (26 mg,
0.11 mmol), 5-methyl-1-phenyl-1H-pyrazole-3-carbaldehyde
(20 mg, 0.11 mmol), and sodium triacetoxyborohydride (46
mg, 0.22 mmol) were combined in DCM (4 mL) according to
General Method 1. Work-up and purification afforded the title
compound. LCMS (ESI) m/z: 410 (M + H)+. 1H NMR (400
MHz, CDCl3): δ 7.48−7.42 (m, 4H), 7.38−7.31 (m, 1H),
7.02−6.92 (m, 1H), 6.85−6.79 (m, 1H), 6.24 (s, 1H), 3.85 (t, J
= 5.5 Hz, 2H), 3.65 (s, 2H), 2.86−2.73 (m, 4H), 2.59−2.41 (m,
4H), 2.34 (d, J = 0.7 Hz, 3H), 1.85−1.77 (m, 2H).
Synthesis of 1′-((5-Methoxy-1-phenyl-1H-pyrazol-3-yl)-
methyl)spiro[isochromane-1,4′-piperidine] (11) (Scheme 1).
Methyl 5-Hydroxy-1-phenyl-1H-pyrazole-3-carboxylate (62).
Phenylhydrazine (5.00 g, 46.24 mmol) in Et2O (100 mL) was
added over 30 min to a mixture of dimethyl but-2-ynedioate
(61) (6.57 g, 46.24 mmol) in Et2O (50 mL). After stirring for 1
h at rt, the reaction mixture was concentrated in vacuo and
redissolved in MeOH (150 mL). This solution was added
dropwise over 1 h to NaOMe (25 wt %) (3.99 mg, 184.94
mmol) in MeOH (150 mL) and the mixture was stirred at rt for
18 h. The solvent was removed in vacuo and 5 N HCl (100 mL)
was added. The resulting precipitate was collected by filtration,
washed with DCM and Et2O, and air-dried to afford 5-hydroxy-
1-phenyl-1H-pyrazole-3-carboxylic acid (8.00 g, 76%). 1H
NMR (400 MHz, DMSO): δ 7.74 (d, J = 7.5 Hz, 2H), 7.51
(dd, J = 7.9, 7.9 Hz, 2H), 7.36 (dd, J = 7.4, 7.4 Hz, 1H), 5.93 (s,
1H). 5-Oxo-1-phenyl-4H-pyrazole-3-carboxylic acid (8.00 g,
39.18 mmol) was mixed in MeOH (150 mL), and a few drops
of concentrated H2SO4 were added. The reaction was heated to
reflux for 48 h and then allowed to cool to rt. The volatiles were
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c05589
ACS Omega 2021, 6, 2284−2311
2297
removed in vacuo and the crude material was purified by flash
chromatography (50−100% EtOAc in heptane) to afford the
title compound as a pale brown solid (4.00 g, 42%). 1H NMR
(400 MHz, DMSO): δ 12.15 (m, 1H), 7.74 (d, J = 7.6 Hz, 2H),
7.51 (dd, J = 7.9, 7.9 Hz, 2H), 7.38 (dd, J = 7.4, 7.4 Hz, 1H),
5.97 (s, 1H), 3.81 (s, 3H).
Methyl 5-Methoxy-1-phenyl-1H-pyrazole-3-carboxylate
(63). Methyl 5-hydroxy-1-phenyl-1H-pyrazole-3-carboxylate
(62) (500 mg, 2.29 mmol) was dissolved in THF (10 mL),
and PPh3 (901 mg, 3.44 mmol) and MeOH (0.12 mL, 2.98
mmol) were added. The reaction mixture was cooled to 0 °C
and DIAD (0.68 mL, 3.44 mmol) was added dropwise. The
reaction mixture was allowed to warm to rt for 18 h. The
reaction mixture was partitioned between H2O and DCM,
passed through a hydrophobic frit, and concentrated in vacuo.
The crude material was purified by flash chromatography (0−
100% EtOAc in heptane) to afford the title compound as a
yellow gum. DIAD side product coeluted but used in the next
step with no further purification. 1H NMR (400 MHz, CDCl3):
δ 7.73 (d, J = 8.1 Hz, 2H), 7.46 (dd, J = 7.8, 7.8 Hz, 2H), 7.36
(dd, J = 7.4, 7.4 Hz, 1H), 6.26 (s, 1H), 4.00 (s, 3H)3.96 (s,
3H).
5-Methoxy-1-phenyl-1H-pyrazole-3-carbaldehyde (71).
Methyl 5-methoxy-1-phenyl-pyrazole-3-carboxylate (63) (600
mg, 2.58 mmol) was mixed with THF (8 mL) and cooled to 0
°C. LiAlH4 (2.58 mL 2.58 mmol) was added dropwise over 10
min. After 1 h, the reaction was quenched with H2O (2 mL)
and 2 M NaOH (2 mL). The resulting slurry was filtered
through a Celite cartridge and concentrated in vacuo. The crude
material was purified by flash chromatography (0−100%
EtOAc in heptane) to afford (5-methoxy-1-phenyl-1H-
pyrazol-3-yl)methanol as a pale yellow gum (180 mg, 32%).
1H NMR (400 MHz, CDCl3): δ 7.70 (d, J = 7.6 Hz, 2H), 7.44
(dd, J = 7.9, 7.9 Hz, 2H), 7.29 (m, 1H) 5.74 (s, 1H), 4.69 (d, J =
5.3 Hz, 2H), 3.97 (s, 3H), 2.60 (s, 1H). (5-Methoxy-1-phenyl-
pyrazol-3-yl)methanol (300 mg, 1.47 mmol) was dissolved in
DCM (10 mL) and MnO2 (319 mg, 3.67 mmol) was added.
The reaction mixture was heated to reflux for 48 h and then
allowed to cool to rt. The reaction mixture was filtered through
a Celite cartridge and washed with DCM. The filtrate was
concentrated in vacuo and purified by flash chromatography
(0−100% EtOAc in heptane) to afford the title compound (220
mg, 70%). 1H NMR (400 MHz, CDCl3): δ 9.92 (s, 1H), 7.76
(d, J = 7.8 Hz, 2H), 7.51 (dd, J = 7.8, 7.8 Hz, 2H), 7.41 (dd, J =
7.4, 7.4 Hz, 1H), 6.22 (s, 1H), 4.02 (s, 3H).
1′-((5-Methoxy-1-phenyl-1H-pyrazol-3-yl)methyl)spiro-
[isochromane-1,4′-piperidine] (11). Spiro[isochromane-1,4′-
piperidine] (40 mg, 0.20 mmol), 5-methoxy-1-phenyl-1H-
pyrazole-3-carbaldehyde (71) (40 mg, 0.20 mmol), and sodium
triacetoxyborohydride (83 mg, 0.39 mmol) were combined in
DCM (2 mL) according to General Method 1. Work-up and
purification afforded 1′-((5-methoxy-1-phenyl-1H-pyrazol-3-
yl)methyl)spiro[isochromane-1,4′-piperidine] as a colorless
gum (40 mg, 50%). HRMS (ESI) m/z: calcd for C24H28N3O2
[M + H+], 390.2181; found, 390.2165. 1H NMR (400 MHz,
CDCl3): δ 7.72 (d, J = 7.6 Hz, 1H), 7.43 (dd, J = 8.0, 8.0 Hz,
1H), 7.27−7.09 (m, 2H), 3.97 (s, 2H), 3.92 (dd, J = 5.5, 5.5 Hz,
1H), 3.63 (s, 1H), 2.89−2.83 (m, 2H), 2.60−2.52 (m, 1H),




late (64). Phenylhydrazine (634 mg, 5.88 mmol) was added to
a solution of methyl 4-cyclopropyl-2,4-dioxo-butanoate (55)
(1.00 g, 5.88 mmol) in EtOH (40 mL) according to General
Method 3a. Work-up and purification afforded the title
compound (1.16 g, 81%). LCMS (ESI) m/z: 243 (M + H)+.
1H NMR (500 MHz, CDCl3): δ 7.63−7.59 (m, 2H), 7.51−7.48
(m, 2H), 7.44−7.40 (m, 1H), 6.50 (s, 1H), 3.92 (s, 3H), 1.81−
1.74 (m, 1H), 1.03−0.97 (m, 2H), 0.82−0.76 (m, 2H).
5-Cyclopropyl-1-phenyl-1H-pyrazole-3-carbaldehyde
(72). Methyl 5-cyclopropyl-1-phenyl-1H-pyrazole-3-carboxy-
late (64) (1.16 g, 4.79 mmol) and DIBAL (1 M in DCM)
(11.97 mL, 11.97 mmol) were combined in DCM (25 mL)
according to General Method 6a. Work-up and purification
afforded the title compound (719 mg, 67%). LCMS (ESI) m/z:
213 (M + H)+. 1H NMR (500 MHz, CDCl3): δ 9.97 (s, 1H),




1,4′-piperidine] (48 mg, 0.24 mmol), 5-cyclopropyl-1-phenyl-
1H-pyrazole-3-carbaldehyde (72) (50 mg, 0.24 mmol), and
sodium triacetoxyborohydride (100 mg, 0.47 mmol) were
combined in DCM (4 mL) according to General Method 1.
Work-up and purification afforded the title compound as a
colorless gum (20 mg, 20%). LCMS (ESI) m/z: 400 (M + H)+.
HRMS (ESI) m/z: calcd for C26H30N3O [M + H
+], 400.2383;
found, 400.2389. 1H NMR (500 MHz, CDCl3): δ 7.65−7.61
(m, 2H), 7.48−7.43 (m, 2H), 7.34 (tdd, J = 7.5, 1.5, 1.2 Hz,
1H), 7.21 (dd, J = 7.8, 1.6 Hz, 1H), 7.18 (td, J = 7.3, 1.6 Hz,
1H), 7.13 (td, J = 7.3, 1.6 Hz, 1H), 7.08 (d, 7.3 Hz, 1H), 5.99
(s, 1H)3.89 (t, J = 5.6 Hz, 2H), 3.63 (s, 2H), 2.87−2.80 (m,
4H), 2.50 (td, J = 11.9, 2.3 Hz, 2H), 2.08 (td, J = 13.2, 4.6 Hz,
2H), 1.93−1.87 (m, 2H), 1.84−1.77 (m, 1H), 1.00−0.95 (m,
2H), 0.82−0.77 (m, 2H).
Synthesis of 1′-((5-(Difluoromethyl)-1-phenyl-1H-pyrazol-
3-yl)methyl)spiro[isochromane-1,4′-piperidine] (13)
(Scheme 1). Ethyl 5-(Difluoromethyl)-1-phenyl-1H-pyrazole-
3-carboxylate (65). Ethyl 5,5-difluoro-2,4-dioxo-pentanoate
(56) (1.00 g, 5.15 mmol) and phenylhydrazine (557 mg, 5.15
mmol) were dissolved in EtOH (40 mL) according to General
Method 3a. Work-up and purification afforded an intermediate
compound. This material was then dissolved in THF, 2 M HCl
was added, and the mixture was heated to reflux for 18 h. The
volatiles were removed in vacuo and the product was extracted
with DCM, dried (hydrophobic frit), and concentrated in vacuo
to afford the title compound as a colorless oil (850 mg, 62%).
LCMS (ESI) m/z: 267 (M + H)+. 1H NMR (500 MHz,
CDCl3): δ 7.55 (s, 6H), 6.63 (t, J = 53.4 Hz, 1H), 4.47 (q, J =
7.1 Hz, 2H), 1.44 (t, J = 7.2 Hz, 3H).
5-(Difluoromethyl)-1-phenyl-1H-pyrazole-3-carbaldehyde
(73). Ethyl 5-(difluoromethyl)-1-phenyl-1H-pyrazole-3-carbox-
ylate (65) (187 mg, 0.70 mmol) and DIBAL (1 M in DCM)
(1.76 mL, 1.76 mmol) were combined in DCM (10 mL) with
MnO2 (1.22 g, 14.05 mmol) added in the second step
according to General Method 6b. Work-up and purification
afforded the title compound as a colorless oil (122 mg, 74%).
1′-((5-(Difluoromethyl)-1-phenyl-1H-pyrazol-3-yl)methyl)-
spiro[isochromane-1,4′-piperidine] (13). Spiro[isochromane-
1,4′-piperidine] (62 mg, 0.30 mmol), 5-(difluoromethyl)-1-
phenyl-1H-pyrazole-3-carbaldehyde (73) (61 mg, 0.27 mmol),
and sodium triacetoxyborohydride (116 mg, 0.55 mmol) were
combined in DCM (4 mL) according to General Method 1.
Work-up and purification afforded the title compound as a
colorless gum (10 mg, 8%). LCMS (ESI) m/z: 428 (M + H)+.
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HRMS (ESI) m/z: calcd for C24H26F2N3O [M + H
+],
410.2053; found, 410.2054. 1H NMR (500 MHz, CDCl3): δ
7.56−7.44 (m, 5H), 7.26−7.19 (m, 2H), 7.17 (td, J = 7.0, 2.0
Hz, 1H), 7.11 (d, J = 7.5 Hz, 1H), 6.80 (s, 1H), 6.65 (t, J = 54
Hz, 3.93 (t, J = 5.5, 2H), 3.74 (s, 2H), 2.89−2.83 (m, 4H), 2.56




(Scheme 1). Ethyl 1-Phenyl-5-(trifluoromethyl)-1H-pyrazole-
3-carboxylate (66). Phenylhydrazine (510 mg, 4.71 mmol) and
ethyl 5,5,5-trifluoro-2,4-dioxo-pentanoate (57) (1.00 g, 4.71
mmol) were dissolved in EtOH (40 mL) according to General
Method 3a. Work-up and purification afforded an intermediate
compound. This material was then dissolved in THF, 2 M HCl
was added, and the mixture was heated to reflux for 18 h. The
volatiles were removed in vacuo, and the product was extracted
with DCM, dried via a hydrophobic frit, and concentrated in
vacuo. The crude material was purified by flash chromatography
(10−50% EtOAc in heptane) to afford the title compound as a
yellow oil (456 mg, 34%). LCMS (ESI)m/z: 285 (M + H)+. 1H
NMR (400 MHz, CDCl3): δ 7.54−7.47 (m, 5H), 7.33 (s, 1H),
4.45 (q, J = 7.2, 2H), 1.41 (t, J = 7.2, 3H).
1-Phenyl-5-(Trifluoromethyl)-1H-pyrazole-3-carbalde-
hyde (74). Ethyl 1-phenyl-5-(trifluoromethyl)-1H-pyrazole-3-
carboxylate (66) (417 mg, 1.47 mmol) and DIBAL (1 M in
DCM) (3.67 mL, 3.67 mmol) were combined in DCM (10
mL) with MnO2 (273 mg, 3.14 mmol) added in the second step
according to General Method 6b. Work-up afforded the crude
product which was used without further purification.
1′-((1-Phenyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)methyl)-
spiro[isochromane-1,4′-piperidine] (14). Spiro[isochromane-
1,4′-piperidine] (49 mg, 0.24 mmol), 1-phenyl-5-(trifluoro-
methyl)-1H-pyrazole-3-carbaldehyde (74) (52 mg, 0.22
mmol), and sodium triacetoxyborohydride (92 mg, 0.43
mmol) were combined in DCM (2 mL) according to General
Method 1. Work-up and purification afforded the title
compound as a colorless gum (20 mg, 21%). LCMS (ESI)
m/z: 428 (M + H)+. 1H NMR (500 MHz, CDCl3): δ 7.51−
7.43 (m, 5H), 7.23−7.17 (m, 1H), 7.09 (d, J = 7.6 Hz, 1H),
6.84 (s, 1H), 3.90 (t, J = 5.5 Hz, 2H), 3.70 (s, 2H), 2.85−2.80
(m, 4H), 2.53 (td, 12.0, 2.5 Hz, 2H), 2.08 (td, 13.3, 4.4 Hz,




[isochromane-1,4′-piperidine] (78). To 5-methyl-1H-pyra-
zole-3-carbaldehyde (1.35 g, 12.30 mmol) in NMP (125 mL)
were added spiro[isochromane-1,4′-piperidine] (2.50 g, 12.30
mmol) and a few drops of acetic acid. After 1 h at rt, sodium
triacetoxyborohydride (5.21 mg, 24.60 mmol) was added. The
reaction mixture was stirred at rt for 18 h. The reaction was
quenched with NaHCO3 (saturated aqueous solution), and the
product was extracted with EtOAc, washed with brine, dried
(Na2SO4), and concentrated in vacuo. The residue was loaded
onto a 20 g SCX cartridge eluting with MeOH and then 20% 2
N NH3/MeOH. The volatiles were removed in vacuo to afford
the title compound as a pale yellow solid (320 mg, 8%). The
initial MeOH washings were concentrated in vacuo, and the
resulting material was purified by flash chromatography (0−5%
MeOH in DCM) to afford a second batch of title compound as
a pale yellow solid (1.60 g, 42%). 1H NMR (400 MHz, CDCl3):
δ 7.22−7.21 (m, 2H), 7.18−7.14 (m, 1H), 7.10 (d, J = 7.34
Hz), 6.02 (s, 1H), 3.91 (t, J = 5.5 Hz, 2H), 3.61 (s, 2H), 2.84 (t,
J = 5.5 Hz, 2H), 2.78−2.75 (m, 2H), 2.49 (t, J = 11.5 Hz, 2H),
2.31 (s, 3H), 2.06 (td, J = 13.5, 3.8 Hz, 2H), 1.93−1.90 (m,




(78) (100 mg, 0.34 mmol), [4-(hydroxymethyl)phenyl]-
boronic acid (102 mg, 0.67 mmol), and copper acetate (92
mg, 0.50 mmol) were combined in DCM (3 mL) and pyridine
(0.50 mL, 6.20 mmol) according to General Method 2. Work-
up and purification afforded the title compound (30 mg, 21%).
HRMS (ESI) m/z: calcd for C25H30N3O2 [M + H
+], 404.2338;
found, 404.2365. 1H NMR (400 MHz, CDCl3): δ 7.43 (s, 4H),
7.25−7.09 (m, 4H), 6.24 (s, 1H), 4.76 (s, 2H), 3.92 (dd, J =
5.5, 5.5 Hz, 2H), 3.68 (s, 2H), 2.89−2.82 (m, 4H), 2.59−2.51
(m, 3H), 2.34 (s, 3H), 2.16−2.06 (m, 2H), 1.92 (d, J = 12.2 Hz,
2H).
Synthesis of 1′-((5-Methyl-1-(p-tolyl)-1H-pyrazol-3-yl)-
methyl)spiro[isochromane-1,4′-piperidine] (16) (Scheme 1).
1′-[(5-methyl-1H-pyrazol-3-yl)methyl]spiro[isochromane-
1,4′-piperidine] (78) (50 mg, 0.17 mmol), p-tolylboronic acid
(46 mg, 0.34 mmol), and copper acetate (46 mg, 0.25 mmol)
were combined in DCM (1 mL) and pyridine (0.27 mL)
according to General Method 2. Work-up and purification
afforded the title compound as a yellow gum (15 mg, 22%).
LCMS (ESI) m/z: 388 (M + H) +. 1H NMR (400 MHz,
CDCl3): δ 7.36−7.32 (m, 2H), 7.28−7.22 (m, 3H), 7.20 (td, J
= 6.83, 1.57 Hz, 1H), 7.15 (td, J = 7.32, 1.8 Hz, 1H), 7.11−7.08
(m, 1H), 6.22 (d, J = 0.5 Hz, 1H), 3.9 (t, J = 5.5 Hz, 2H), 6.37
(s, 2H), 2.90−2.83 (m, 4H), 2.53 (td, J = 12.90, 2.44 Hz, 2H),
2.41 (s, 3H), 2.33 (d, J = 0.7 Hz, 3H), 2.10 (td, J = 13.40, 4.47
Hz, 2H), 1.95−1.89 (m, 2H).
Synthesis of 1′-((5-Methyl-1-(4-(trifluoromethoxy)phenyl)-
1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine]
(17) (Scheme 1). Ethyl 5-Methyl-1-(4-(trifluoromethoxy)-
pheny l ) - 1H -p y r a zo l e - 3 - c a r box y l a t e (67 ) . [ 4 -
(Trifluoromethoxy)phenyl]hydrazine hydrochloride (4.34 g,
18.97 mmol) and ethyl 2,4-dioxopentanoate (58) (3.00 g, 18.97
mmol) were dissolved in AcOH (25 mL) according to General
Method 3b. Work-up and purification afforded the title
compound (3.00 g, 48%). 1H NMR (400 MHz, CDCl3): δ
7.55−7.52 (m, 2H), 7.35 (d, J = 8.3 Hz, 2H), 6.77 (s, 1H), 4.44
(q, J = 7.1 Hz, 2H), 2.37 (s, 3H).
5-Methyl-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazole-3-
carbaldehyde (75). Ethyl 5-methyl-1-[4-(trifluoromethoxy)-
phenyl]pyrazole-3-carboxylate (67) (2.60 g, 8.27 mmol) and
DIBAL (1 M in DCM) (20.68 mL, 20.68 mmol) were
combined in DCM (25 mL) according to General Method 6a.
Work-up and purification afforded the title compound as a pale
yellow oil (2.00 g, 85%). 1H NMR (400 MHz, CDCl3): δ 10.01
(s, 1H), 7.58−7.55 (m, 2H), 7.41 (d, J = 8.3 Hz, 2H), 6.76 (s,
1H), 2.41 (s, 3H).
1′-((5-Methyl-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-
3-yl)methyl)spiro[isochromane-1,4′-piperidine] (17). Spiro-
[isochromane-1,4′-piperidine] (250 mg, 1.23 mmol), 5-methyl-
1-[4-(trifluoromethoxy)phenyl]-1H-pyrazole-3-carbaldehyde
(75) (332 mg, 1.23 mmol), and sodium triacetoxyborohydride
(521 mg, 2.46 mmol) were combined in DCM (2 mL)
according to General Method 1. Work-up and purification
afforded the title compound (300 mg, 51%). HRMS (ESI)m/z:
calcd for C25H27F3N3O2 [M + H
+], 458.2055; found, 458.2073.
1H NMR (400 MHz, CDCl3): δ 7.52 (d, J = 8.8 Hz, 2H), 7.32
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(d, J = 8.8 Hz, 2H), 7.23−7.08 (m, 4H), 6.26 (s, 1H), 3.92 (dd,
J = 5.5, 5.5 Hz, 2H), 3.66 (s, 2H), 2.88−2.83 (m, 4H), 2.54 (dd,
J = 11.3, 11.3 Hz, 2H), 2.37 (s, 3H), 2.15−2.05 (m, 2H), 1.94
(d, J = 12.9 Hz, 2H).
Synthesis of 1′-((1-(6-Methoxypyridin-3-yl)-5-methyl-1H-
pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (18)
(Scheme 1). Ethyl 1-(6-Methoxypyridin-3-yl)-5-methyl-1H-
pyrazole-3-carboxylate (68). Ethyl 5-methyl-1H-pyrazole-3-
carboxylate (60) (500 mg, 3.24 mmol), (6-methoxypyridin-3-
yl)boronic acid (992 mg, 6.49 mmol), and copper acetate (884
mg, 4.86 mmol) were combined in DCM (10 mL) according to
General Method 2. Work-up and purification afforded the title
compound (340 mg, 38%). 1H NMR (400 MHz, CDCl3): δ
8.23 (d, J = 2.7 Hz, 1H), 7.65 (dd, J = 2.7, 8.8 Hz, 1H), 6.85−
6.81 (m, 2H), 4.26 (q, J = 7.1 Hz, 2H), 4.00 (s, 3H), 2.38 (s,
3H), 1.29 (dd, J = 7.2, 7.2 Hz, 3H).
1-(6-Methoxypyridin-3-yl)-5-methyl-1H-pyrazole-3-car-
baldehyde (76). Ethyl 1-(6-methoxy-3-pyridyl)-5-methyl-1H-
pyrazole-3-carboxylate (68) (380 mg, 1.45 mmol) and DIBAL
(1 M in DCM) (3.64 mL, 3.64 mmol) were combined in DCM
(10 mL) according to General Method 6a. Work-up and
purification afforded the title compound (270 mg, 81%). 1H
NMR (400 MHz, CDCl3): δ 10.00 (s, 1H), 8.31−8.30 (m,
1H), 7.72 (dd, J = 2.8, 8.8 Hz, 1H), 6.92 (d, J = 8.8 Hz, 1H),
6.75 (s, 1H), 4.03 (s, 3H), 2.36 (s, 3H).
1′-((1-(6-Methoxypyridin-3-yl)-5-methyl-1H-pyrazol-3-yl)-
methyl)spiro[isochromane-1,4′-piperidine] (18). Spiro-
[isochromane-1,4′-piperidine] (120 mg, 0.59 mmol), 1-(6-
methoxy-3-pyridyl)-5-methyl-1H-pyrazole-3-carbaldehyde
(76) (128 mg, 0.59 mmol), and sodium triacetoxyborohydride
(250 mg, 1.18 mmol) were combined in DCM (2 mL)
according to General Method 1. Work-up and purification
afforded the title compound (150 mg, 60%). HRMS (ESI)m/z:
calcd for C24H29N4O2 [M + H
+], 405.2288; found, 405.2292.
1H NMR (400 MHz, CDCl3): δ 8.25 (d, J = 2.2 Hz, 1H), 7.72
(dd, J = 2.4, 8.8 Hz, 1H), 7.23−7.09 (m, 4H), 6.85 (d, J = 8.8
Hz, 1H), 6.24 (s, 1H), 4.00 (s, 3H), 3.92 (dd, J = 5.5, 5.5 Hz,
2H), 3.66 (s, 2H), 2.88−2.83 (m, 4H), 2.53 (dd, J = 11.4, 11.4




peridine] (19) (Scheme 1). 1′-[(5-methyl-1H-pyrazol-3-yl)-
methyl]spiro[isochromane-1,4′-piperidine] (78) (100 mg, 0.34
mmol), 2-(difluoromethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-diox-
aborolan-2-yl)pyridine (182 mg, 0.67 mmol), and copper
acetate (92 mg, 0.50 mmol) were combined in DCM (3 mL)
and pyridine (0.50 mL, 6.20 mmol) according to General
Method 2. Work-up and purification afforded the title
compound (10 mg, 6%). HRMS (ESI) m/z: calcd for
C24H27F2N4O2 [M + H
+], 441.2102; found, 441.2108. 1H
NMR (400 MHz, CDCl3): δ 8.32 (d, J = 2.5 Hz, 1H), 7.91 (dd,
J = 2.7, 8.7 Hz, 1H), 7.23−7.02 (m, 5H), 6.27 (s, 1H), 3.92 (dd,
J = 5.5, 5.5 Hz, 2H), 3.66 (s, 2H), 2.85 (dd, J = 5.5, 5.5 Hz, 4H),
2.54 (dd, J = 11.0, 11.0 Hz, 2H), 2.36 (s, 3H), 2.14−2.07 (m,
2H), 1.93 (d, J = 12.0 Hz, 2H).
Synthesis of 1′-((5-Methyl-1-(6-(trifluoromethyl)pyridin-3-
yl)-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperi-
dine] (20) (Scheme 1). Ethyl 5-Methyl-1-(6-(trifluoromethyl)-
pyridin-3-yl)-1H-pyrazole-3-carboxylate (69). [6-(Trifluoro-
methyl)-3-pyridyl]hydrazine (2.46 g, 13.91 mmol) and ethyl
2,4-dioxopentanoate (59) (2.20 g, 13.91 mmol) were dissolved
in AcOH (20 mL) according to General Method 3b. Work-up
and purification afforded the title compound (2.70 g, 62%). 1H
NMR (400 MHz, CDCl3): δ 8.83 (d, J = 2.4 Hz, 1H), 8.01 (dd,
J = 2.1, 8.3 Hz, 1H), 7.80 (d, J = 8.3 Hz, 1H), 6.93 (s, 1H), 4.30
(q, J = 7.1 Hz, 2H), 2.40 (s, 3H), 1.32 (dd, J = 7.1, 7.1 Hz, 3H).
5-Methyl-1-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazole-
3-carbaldehyde (77). Ethyl 5-methyl-1-[6-(trifluoromethyl)-3-
pyridyl]-1H-pyrazole-3-carboxylate (69) (1.45 mg, 4.85 mmol)
and DIBAL (1 M in DCM) (12.11 mL, 12.11 mmol) were
combined in DCM (10 mL) according to General Method 6a.
Work-up and purification afforded the title compound (1.00 g,
77%). 1H NMR (400 MHz, CDCl3): δ 10.04 (s, 1H), 8.98 (d, J
= 2.3 Hz, 1H), 8.13 (dd, J = 2.2, 8.3 Hz, 1H), 7.91 (d, J = 8.4
Hz, 1H), 6.82 (s, 1H), 2.51 (s, 3H).
1′-((5-Methyl-1-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyra-
zol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (20).
Spiro[isochromane-1,4′-piperidine] (40 mg, 0.20 mmol), 5-
methyl-1-[6-(trifluoromethyl)-3-pyridyl]-1H-pyrazole-3-carbal-
dehyde (77) (50 mg, 0.20 mmol), and sodium triacetoxybor-
ohydride (83 mg, 0.39 mmol) were combined in DCM (2 mL)
according to General Method 1. Work-up and purification
afforded the title compound as a colorless gum (40 mg, 43%).
HRMS (ESI) m/z: calcd for C24H26F3N4O [M + H
+],
443.2058; found, 443.2039. 1H NMR (400 MHz, CDCl3): δ
8.93 (d, J = 2.2 Hz, 1H), 8.10 (dd, J = 2.2, 8.5 Hz, 1H), 7.82 (d,
J = 8.5 Hz, 1H), 7.22−7.09 (m, 4H), 6.33 (s, 1H), 3.92 (dd, J =
5.5, 5.5 Hz, 2H), 3.67 (s, 2H), 2.86 (dd, J = 5.5, 5.5 Hz, 4H),
2.59−2.51 (m, 2H), 2.48 (s, 3H), 2.15−2.03 (m, 2H), 1.93 (d, J
= 12.4 Hz, 2H).
Synthesis of 2-(5-Methyl-3-(spiro[isochromane-1,4′-piper-
idin]-1′-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (21)
(Scheme 1). Spiro[isochromane-1,4′-piperidine] (71 mg, 0.35
mmol), tert-butyl 2-(3-formyl-5-methyl-1H-pyrazol-1-yl)-
benzoate (100 mg, 0.35 mmol), and sodium triacetoxyborohy-
dride (148 mg, 0.70 mmol) were combined in DCM (2 mL)
according to General Method 1. Work-up and purification
afforded tert-butyl 2-(5-methyl-3-(spiro[isochromane-1,4′-pi-
peridin]-1′-ylmethyl)-1H-pyrazol-1-yl)benzoate as a colorless
gum (125 mg, 68%). 1H NMR (500 MHz, CDCl3): δ 7.91 (dd,
J = 1.7, 7.6 Hz, 1H), 7.62−7.49 (m, 2H), 7.36 (d, J = 7.6 Hz,
1H), 7.25−7.09 (m, 3H), 5.32 (s, 1H), 4.72 (s, 1H), 3.90 (dd, J
= 5.5, 5.5 Hz, 2H), 2.84 (dd, J = 5.4, 5.4 Hz, 2H), 2.57−2.56
(m, 1H), 2.18 (s, 4H), 1.93 (d, J = 13.4 Hz, 2H), 1.38 (d, J = 3.2
Hz, 12H), 1.30−1.25 (m, 1H). tert-Butyl 2-[5-methyl-3-
(spiro[isochromane-1,4′-piperidine]-1′-ylmethyl)-1H-pyrazol-
1-yl]benzoate (125 mg, 0.26 mmol) was then stirred in TFA (2
mL) at rt for 18 h and then concentrated in vacuo. The residue
was loaded onto a 1 g SCX cartridge, eluting with 3 M NH3/
MeOH. The crude product was purified by preparative HPLC
(XBridge column, 0.1% NH4OH modifier) to afford the title
compound (80 mg, 69%). HRMS (ESI) m/z: calcd for
C25H28N3O3 [M + H
+], 418.2125; found, 418.2120. 1H NMR
(400 MHz, CDCl3): δ 7.97 (dd, J = 1.7, 7.4 Hz, 1H), 7.55−7.45
(m, 2H), 7.36 (dd, J = 1.4, 7.6 Hz, 1H), 7.25−7.05 (m, 4H),
6.37 (s, 1H), 4.01 (s, 2H), 3.81 (dd, J = 5.4, 5.4 Hz, 2H), 3.34
(dd, J = 2.1, 9.1 Hz, 2H), 3.07 (dd, J = 11.6, 11.6 Hz, 2H), 2.79
(dd, J = 5.3, 5.3 Hz, 2H), 2.58−2.49 (m, 2H), 2.31 (s, 3H), 1.92




yl)benzoic Acid (87). Ethyl 2,4-dioxopentanoate (79) (10.29 g,
65.07 mmol) was dissolved in EtOH (100 mL) and 3-
hydrazinobenzoic acid (9.90 g, 65.07 mmol) was added. The
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reaction was heated to reflux for 1 h and then allowed to cool to
rt. The solvent was removed in vacuo and H2O was added. The
product was extracted with EtOAc, dried (hydrophobic frit),
and concentrated in vacuo to afford a mixture of isomers
(approximately 1:4 in favor of the desired isomer) (16.48 g, 60
mmol total). No attempt was made to separate the regioisomers
at this stage, and the crude material was taken through to the
next step without further purification. LCMS (ESI+) m/z: 275
(M + H)+. 1H NMR (500 MHz, CDCl3): δ 8.20−8.12 (m, 2H),
7.74 (d, J = 8.0, 1H), 7.59 (t, J = 7.8, 1H), 6.76 (s, 1H), 4.41 (q,
J = 7.1, 2H), 1.39 (t, J = 7.1, 3H).
Ethyl 1-(3-(4,5-Dihydrooxazol-2-yl)phenyl)-5-methyl-1H-
pyrazole-3-carboxylate (93). A mixture of 3-(3-ethoxycarbon-
yl-5-methyl-1H-pyrazol-1-yl)benzoic acid and 3-(5-ethoxycar-
bonyl-3-methyl-1H-pyrazol-1-yl)benzoic acid (87) (5.00 g,
18.23 mmol in total as a mixture of isomers) was dissolved in
thionyl chloride (3.99 mL, 54.69 mmol), and three drops of
pyridine were added. The mixture was heated to 50 °C for 1 h
and then allowed to cool to rt. The mixture was concentrated in
vacuo and the resulting oil was dissolved in DCM (20 mL).
Ethanolamine (2.19 mL, 36.46 mmol) was added dropwise and
the mixture was stirred for 3 h at rt. Further, thionyl chloride
(3.99 mL, 54.69 mmol) was added to convert the OH to Cl.
This mixture was stirred at rt for 18 h. The reaction was
quenched with the dropwise addition of H2O. The aqueous
layer was basified with 2 M NaOH and extracted with DCM.
The organics were separated, dried (hydrophobic frit), and
concentrated in vacuo to afford a brown oil. The crude material
was purified by flash chromatography (10−50% EtOAc in
heptane). The second compound to elute was the desired
isomer. This solid was dissolved in THF, cooled to 0 °C, and
sodium hydride (60% in mineral oil) (729 mg, 18.23 mmol)
was added. The reaction mixture was allowed to warm to rt and
stirred for 2 h. The reaction was quenched carefully with water
at 0 °C. The volatiles were removed in vacuo and the product
was extracted with EtOAc, dried (hydrophobic frit), and
concentrated in vacuo to afford the title compound (2.1 g,
38%). LCMS (ESI) m/z: 300 (M + H)+. 1H NMR (500 MHz,
CDCl3): δ 8.03−7.98 (m, 2H), 7.60 (d, J = 7.9 Hz, 1H), 7.52 (t,
J = 7.9 Hz, 1H), 6.73 (s, 1H), 4.48−4.36 (m, 4H), 4.07 (t, J =
9.5 Hz, 2H), 2.34 (s, 3H), 1.39 (t, J = 7.0 Hz, 3H).
1-(3-(4,5-Dihydrooxazol-2-yl)phenyl)-5-methyl-1H-pyra-
zole-3-carbaldehyde (99). Ethyl 1-[3-(4,5-dihydrooxazol-2-
yl)phenyl]-5-methyl-1H-pyrazole-3-carboxylate (93) (2.10 g,
7.02 mmol) and DIBAL (1 M in DCM) (17.54 mL, 17.54
mmol) were combined in DCM (20 mL) with MnO2 (6.10 g,
70.16 mmol) added in the second step according to General
Method 5b. Work-up and purification afforded the title
compound, which was used without further purification.
1′-((1-(3-(4,5-Dihydrooxazol-2-yl)phenyl)-5-methyl-1H-
pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine]
(105). Spiro[isochromane-1,4′-piperidine] (80 mg, 0.39
mmol), 1-[3-(4,5-dihydrooxazol-2-yl)phenyl]-5-methyl-1H-
pyrazole-3-carbaldehyde (99) (100 mg, 0.39 mmol), and
sodium triacetoxyborohydride (166 mg, 0.78 mmol) were
combined in DCM (20 mL) according to General Method 1.
Work-up and purification afforded the title compound (30 mg,
16%). LCMS (ESI) m/z: 442 (M + H)+. 1H NMR (400 MHz,
CDCl3): δ 8.02 (s, 1H), 7.94 (d, J = 7.5 Hz, 1H), 7.61 (d, J =
7.9 Hz, 1H), 7.50 (t, J = 7.9 Hz, 1H), 7.24−7.10 (m, 3H), 7.08
(d, J = 7.5 Hz, 1H), 6.24 (s, 1H), 4.45 (t, J = 9.5 Hz, 2H), 4.08
(t, J = 9.5 Hz, 2H), 3.92−3.87 (m, 2H), 3.66 (s, 2H), 2.89−
2.79 (m, 4H), 2.53 (t, J = 11.6 Hz, 2H), 2.36 (s, 3H), 2.09 (t, J
= 13.3 Hz, 2H, 1.91 (d, J = 13.3 Hz, 2H).
3-(5-Methyl-3-(spiro[isochromane-1,4′-piperidin]-1′-yl-
methyl)-1H-pyrazol-1-yl)benzoic Acid (22). 1′-[[1-[3-(4,5-
Dihydrooxazol-2-yl)phenyl]-5-methyl-1H-pyrazol-3-yl]-
methyl]spiro[isochromane-1,4′-piperidine] (105) (30 mg, 0.07
mmol) was dissolved in 3 M HCl according to General Method
3. Work-up and purification afforded the title compound (19
mg, 66%). LCMS (ESI) m/z: 418 (M + H)+. HRMS (ESI) m/
z: calcd for C25H28N3O3 [M + H
+], 418.2130; found, 418.2133.
1H NMR (400 MHz, CDCl3): δ 8.24−8.16 (m, 2H), 7.53 (d, J
= 4.2 Hz, 2H), 7.21−7.02 (m, 4H), 6.44 (s, 1H), 4.17 (s, 2H),
3.88−3.83 (m, 2H), 3.44 (d, J = 10.9 Hz, 2H), 3.13−3.03 (m,
2H), 2.82−2.76 (m, 2H), 2.53 (t, J = 13.3 Hz, 2H), 2.32 (s,




yl)benzoic Acid (88). Ethyl 2,4-dioxopentanoate (10.39 g,
65.73 mmol) was dissolved in EtOH (100 mL) and 4-
hydrazinobenzoic acid (80) (10.0 g, 65.73 mmol) was added.
The reaction mixture was heated to reflux for 2 h and then
allowed to cool to rt. The solvent was removed in vacuo, H2O
was added, and the product was extracted with EtOAc. The
organics were separated, dried (hydrophobic frit), and
concentrated in vacuo to afford a mixture of isomers
(approximately 1:4 in favor of the desired isomer) 4-(5-
ethoxycarbonyl-3-methyl-1H-pyrazol-1-yl)benzoic acid and 4-
(3-ethoxycarbonyl-5-methyl-1H-pyrazol-1-yl)benzoic acid. No
attempt was made to separate the regioisomers at this stage and
the crude material was taken onto the next step without further
purification. LCMS (ESI) m/z: 275 (M + H)+. 1H NMR (500
MHz, CDCl3): δ 8.24 (d, J = 8.3, 2H), 7.63 (d, J = 8.3, 2H),
6.78 (s, 1H), 4.43 (q, J = 7.1, 2H), 2.41 (s, 3H), 1.41 (t, J = 7.1,
3H) (major isomer reported).
Ethyl 1-(4-(4,5-Dihydrooxazol-2-yl)phenyl)-5-methyl-1H-
pyrazole-3-carboxylate (94). A mixture of 4-(3-ethoxycarbon-
yl-5-methyl-1H-pyrazol-1-yl)benzoic acid and 4-(5-ethoxycar-
bonyl-3-methyl-1H-pyrazol-1-yl)benzoic acid (88) (18.82 g,
68.62 mmol in total as a mixture of isomers) was dissolved in
thionyl chloride (20.02 mL, 274.48 mmol), and three drops of
pyridine were added. The mixture was heated to 50 °C for 2 h
and then allowed to cool to rt. The mixture was concentrated in
vacuo, and the resulting oil was dissolved in DCM (20 mL).
Ethanolamine (8.26 mL, 137.24 mmol) was added dropwise
and the mixture was stirred for 3 h at rt. Further thionyl chloride
(20.01 mL, 274.48 mmol) was added to convert the OH to Cl.
This mixture was stirred at rt for 18 h. The reaction was
quenched with the dropwise addition of H2O. The aqueous
layer was basified with 2 M NaOH and extracted with EtOAc.
The organics were separated, dried (hydrophobic frit), and
concentrated in vacuo to afford a brown oil. The crude material
was purified by flash chromatography (10−50% EtOAc in
heptane). The second compound to elute was the desired
isomer, ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-5-methyl-
1H-pyrazole-3-carboxylate (10.62 g, 44%). LCMS (ESI) m/z:
336 (M + H)+. 1H NMR (400 MHz, CDCl3): δ 7.91 (d, J = 8.1
Hz, 2H), 7.57 (d, J = 8.1 Hz, 2H), 6.75 (s, 1H), 4.42 (q, J = 7.1
Hz, 2H), 3.86−3.80 (m, 2H), 3.79−3.74 (m, 2H), 2.37 (s, 3H),
1.40 (t, J = 7.1 Hz, 3H). Ethyl 1-[4-(2-chloroethylcarbamoyl)-
phenyl]-5-methyl-1H-pyrazole-3-carboxylate (10.62 g, 31.63
mmol) was dissolved in THF (50 mL) and cooled to 0 °C.
NaH (759 mg, 31.63 mmol) was added portionwise waiting for
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the effervescence to cease each time. The reaction was allowed
to stir at 0 °C for 3 h and then carefully quenched by adding
H2O dropwise. The mixture was allowed to warm to rt and
TBME was added. The organics were separated, dried
(hydrophobic frit), and concentrated in vacuo to afford the
title compound, which was used without further purification.
LCMS (ESI) m/z: 300 (M + H)+. 1H NMR (500 MHz,
CDCl3): δ 8.06 (d, J = 8.4 Hz, 2H), 7.54 (d, J = 8.4 Hz, 2H),
6.75 (s, 2H), 4.47 (t, J = 9.6 Hz, 2H), 4.42 (q, J = 7.1, 2H), 4.09
(t, J = 9.6 Hz, 2H), 2.37 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H).
1-(4-(4,5-Dihydrooxazol-2-yl)phenyl)-5-methyl-1H-pyra-
zole-3-carbaldehyde (100). Ethyl 1-[4-(4,5-dihydrooxazol-2-
yl)phenyl]-5-methyl-1H-pyrazole-3-carboxylate (94) (9.75 g,
32.57 mmol) and DIBAL (1 M in DCM) (6.51 mL, 6.51
mmol) were combined in DCM (90 mL) with MnO2 (14.16 g,
162.87 mmol) added in second step according to General
Method 5b. Work-up and purification afforded the title
compound (5.14 g, 59%). LCMS (ESI) m/z: 256 (M + H)+.
1H NMR (500 MHz, CDCl3): δ 10.00 (s, 1H), 8.11 (d, J = 8.5
Hz, 2H), 7.56 (d, J = 8.5 Hz, 2H), 6.73 (s, 1H), 4.48 (t, J = 9.5
Hz, 2H), 4.10 (t, J = 9.5 Hz, 2H), 2.40 (s, 3H).
1′-((1-(4-(4,5-Dihydrooxazol-2-yl)phenyl)-5-methyl-1H-
pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine]
(106). Spiro[isochromane-1,4′-piperidine] (1.79 g, 8.81
mmol), 1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-5-methyl-1H-
pyrazole-3-carbaldehyde (100) (2.5 g, 8.81 mmol), and sodium
triacetoxyborohydride (3.74 g, 17.63 mmol) were combined in
DCM (4 mL) according to General Method 1. The crude
material was purified by flash chromatography on a KPNH
column (eluting with 10−50% EtOAc in heptane) to afford the
title compound (1.99 g, 48%). LCMS (ESI) m/z: 443 (M +
H)+. 1H NMR (500 MHz, CDCl3): δ 8.03 (d, J = 8.5 Hz, 2H),
7.54 (d, J = 8.5 Hz, 2H), 7.22−7.15 (m, 2H), 7.13 (t, J = 7.3 Hz,
1H), 7.08 (d, J = 7.3 Hz, 1H), 6.24 (s, 1H), 4.46 (t, J = 9.5 Hz,
2H), 4.09 (t, J = 9.5 Hz, 2H), 3.92−3.87 (m, 2H), 3.65 (s, 2H),
2.87−2.80 (m, 4H), 2.52 (t, J = 11.8 Hz, 2H), 1.90 (d, J = 13.4
Hz, 2H).
4-(5-Methyl-3-(spiro[isochromane-1,4′-piperidin]-1′-yl-
methyl)-1H-pyrazol-1-yl)benzoic Acid (23). 1′-[[1-[4-(4,5-
Dihydrooxazol-2-yl)phenyl]-5-methyl-1H-pyrazol-3-yl]-
methyl]spiro[isochromane-1,4′-piperidine] (106) (1.9 g, 4.29
mmol) was dissolved in 3 M HCl according to General Method
4. Work-up and purification afforded the title compound (1 g,
55%). LCMS (ESI) m/z: 418 (M + H)+. HRMS (ESI) m/z:
calcd for C25H28N3O3 [M + H
+], 418.2130; found, 418.2159.
1H NMR (400 MHz, CD3OD): δ 8.11 (d, J = 8.1 Hz, 2H), 7.52
(d, J = 8.1 Hz, 2H), 7.24−7.11 (m, 4H), 6.48 (s, 1H), 4.30 (s,
1H), 3.94 (t, J = 5.4 Hz, 2H), 3.45 (d, J = 11.4 Hz, 2H), 3.36 (d,
J = 12.5 Hz, 2H), 2.87−2.80 (m, 2H), 2.40 (s, 3H), 2.31 (td, J =
13.7, 3.8 Hz, 2H), 2.11 (d, J = 14.6 Hz, 2H).
Synthesis of 4-(5-Ethyl-3-(spiro[isochromane-1,4′-piperi-
din]-1′-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (24) (Scheme
2). Lithium 4-(3-(Ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)-
benzoate (87). 4-Aminobenzoic acid (2.00 g, 14.58 mmol) was
suspended in H2O (30 mL) and cooled to 0 °C. Concentrated
H2SO4 (15 mL, 14.58 mmol) was added dropwise to this
suspension, followed by the dropwise addition of NaNO2 (5%
aqueous solution) (20 mL, 14.58 mmol). The reaction mixture
was stirred for 30 min at 0 °C, then NaBF4 (17% aqueous
solution) (12 mL, 14.58 mmol) was added, and the reaction
was stirred for further 30 min. A solution of ethyl 2-chloro-3-
oxo-butanoate (2.40 g, 14.58 mmol) in MeOH (75 mL) was
added to the reaction mixture, which was then allowed to warm
to rt and stirred for 3 h. The resulting precipitate was filtered,
washed with H2O, and air-dried to afford (E)-4-(2-(1-chloro-2-
ethoxy-2-oxoethylidene)hydrazinyl)benzoic acid (3.00 g, 72%).
1H NMR (400 MHz, DMSO): δ 12.65−12.65 (m, 1H), 10.84
(s, 1H), 7.92 (d, J = 8.7 Hz, 2H), 7.43 (d, J = 8.7 Hz, 2H), 4.32
(q, J = 7.1 Hz, 2H), 1.31 (dd, J = 7.1, 7.1 Hz, 3H). (E)-4-(2-(1-
Chloro-2-ethoxy-2-oxoethylidene)hydrazinyl)benzoic acid
(1.30 g, 4.80 mmol) and 1-diethoxyphosphorylbutan-2-one
(1.00 g, 4.80 mmol) were mixed in diglyme (15 mL) and LiOH
(504 mg, 12.01 mmol) was added. The reaction mixture was
stirred at rt for 18 h. The reaction mixture was concentrated in
vacuo to afford the title compound and was used directly in the
next step without further purification.
Ethyl 1-(4-(4,5-Dihydrooxazol-2-yl)phenyl-5-ethyl-1H-pyr-
azole-3-carboxylate) (95). Lithium 4-(3-ethoxycarbonyl-5-
ethyl-1H-pyrazol-1-yl)benzoate (89) (1.40 g, 4.76 mmol) was
mixed in thionyl chloride (3 mL, 18.66 mmol) and heated to
reflux for 2 h. The reaction mixture was allowed to cool to rt
and then concentrated in vacuo. The resulting orange solid was
suspended in DCM (20 mL) and cooled to 0 °C. 2-
Chloroethanamine hydrochloride (607 mg, 5.23 mmol) and
DIPEA (3.32 mL, 19.03 mmol) were added, and the reaction
mixture was allowed to warm up to rt for 18 h. The reaction was
quenched with H2O, passed through a hydrophobic frit, and
concentrated in vacuo. The crude material was purified by flash
chromatography (eluting with 0−100% EtOAc in heptane) to
afford ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-5-ethyl-1H-
pyrazole-3-carboxylate (1.00 g, 57%). 1H NMR (400 MHz,
CDCl3): δ 7.93 (d, J = 8.6 Hz, 2H), 7.58 (d, J = 8.6 Hz, 2H),
6.82 (s, 1H), 6.67 (d, J = 5.0 Hz, 1H), 4.45 (q, J = 7.1 Hz, 2H),
3.88−3.78 (m, 4H), 2.71 (q, J = 7.5 Hz, 2H), 1.43 (dd, J = 7.1,
7.1 Hz, 3H), 1.30−1.25 (m, 3H). Ethyl 1-[4-(2-
chloroethylcarbamoyl)phenyl]-5-ethyl-1H-pyrazole-3-carboxy-
late (1.00 g, 2.86 mmol) was dissolved in THF (30 mL) and
cooled to 0 °C. NaH (126 mg, 3.14 mmol) was added, and the
reaction mixture was allowed to warm to rt for 18 h and then
heated to 50 °C for 1 h. The reaction was allowed to cool to rt
and then quenched with H2O. The volatiles were removed in
vacuo, and the product was extracted with EtOAc. The
combined organics were washed with brine, dried (hydro-
phobic frit), and concentrated in vacuo to afford the title
compound (820 mg, 87%). 1H NMR (400 MHz, CDCl3): δ
8.09 (d, J = 8.6 Hz, 2H), 7.54 (d, J = 8.7 Hz, 2H), 6.81 (s, 1H),
4.53−4.42 (m, 4H), 4.12 (dd, J = 9.5, 9.5 Hz, 2H), 2.71 (q, J =
7.4 Hz, 2H), 1.43 (dd, J = 7.1, 7.1 Hz, 3H), 1.27 (dd, J = 7.5, 7.5
Hz, 3H).
1-(4-(4,5-Dihydrooxazol-2-yl)phenyl)-5-ethyl-1H-pyra-
zole-3-carbaldehyde (101). Ethyl 1-[4-(4,5-dihydrooxazol-2-
yl)phenyl]-5-ethyl-1H-pyrazole-3-carboxylate (95) (820 mg,
2.62 mmol) and DIBAL (1 M in DCM) (6.54 mL, 6.54 mmol)
were combined in DCM (25 mL) according to General Method
5a. Work-up and purification afforded the title compound (600
mg, 81%). 1H NMR (400 MHz, CDCl3): δ 10.03 (s, 1H), 8.13
(d, J = 8.6 Hz, 2H), 7.57 (d, J = 8.7 Hz, 2H), 6.80 (s, 1H), 4.51
(dd, J = 9.5, 9.5 Hz, 2H), 4.14 (dd, J = 9.5, 9.5 Hz, 2H), 2.74 (q,
J = 7.5 Hz, 2H), 1.28 (dd, J = 7.5, 7.5 Hz, 3H).
4-(5-Ethyl-3-(spiro[isochromane-1,4′-piperidin]-1′-yl-
methyl)-1H-pyrazol-1-yl)benzoic Acid (24). Spiro-
[isochromane-1,4′-piperidine] (175 mg, 0.86 mmol), 1-[4-
(4,5-dihydrooxazol-2-yl)phenyl]-5-ethyl-1H-pyrazole-3-carbal-
dehyde (101) (232 mg, 0.86 mmol), and sodium triacetox-
yborohydride (365 mg, 1.72 mmol) were combined in DCM (5
mL) according to General Method 1. The crude oxazoline
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intermediate was dissolved in 3 M HCl (3 mL) according to
General Method 3. Work-up and purification afforded 4-[5-
ethyl-3-(spiro[isochromane-1,4′-piperidine]-1′-ylmethyl)-1H-
pyrazol-1-yl]benzoic acid (200 mg, 51%). LCMS (ESI) m/z:
432.2 (M + H)+. 1H NMR (400 MHz, CDCl3): δ 8.13 (d, J =
8.5 Hz, 2H), 7.37−7.30 (m, 2H), 7.22−7.10 (m, 4H), 6.37 (s,
1H), 4.09 (s, 2H), 3.94 (dd, J = 5.4, 5.4 Hz, 2H), 3.48−3.48 (m,
2H), 3.05 (dd, J = 11.4, 11.4 Hz, 2H), 2.87 (dd, J = 5.2, 5.2 Hz,
2H), 2.73−2.58 (m, 4H), 2.04 (d, J = 13.7 Hz, 2H), 1.19 (dd, J
= 7.5, 7.5 Hz, 3H).
Synthesis of 4-(5-Isopropyl-3-(spiro[isochromane-1,4′-pi-
peridin]-1′-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (25)
(Scheme 2). 1,1-Diethoxy-5-methyl-hexane-2,4-dione (81).
Ethyl 2,2-diethoxyacetate (4.2 mL, 23 mmol) was added
portionwise to a solution of 3-methylbutan-2-one (2 g, 23
mmol) in toluene (10 mL) at 0 °C. NaH (60% dispersion, 2.5
mL g, 46 mmol) was added portionwise, and the mixture was
stirred at 0 °C for 2 h. H2O was added dropwise until the
reaction was quenched, followed by 3 M HCl solution,
dropwise, until the solution was pH 5. The organics were
extracted with DCM, passed through a hydrophobic frit, and
concentrated in vacuo to afford the title compound, which was
used in the next step with no further purification.
4-(3-Formyl-5-isopropyl-1H-pyrazol-1-yl)benzoic Acid
(84). 1,1-Diethoxy-5-methyl-hexane-2,4-dione (83) (386 mg,
1.78 mmol) and 4-hydrazinobenzoic acid (80) (272 mg, 1.78
mmol) were dissolved in EtOH (2 mL) and H2O (2 mL). The
mixture was stirred at 35 °C for 18 h and then allowed to cool
to rt and concentrated in vacuo to afford an orange solid. The
crude material was triturated with Et2O and filtered to afford
the title compound (349 mg, 72%). LCMS (ESI) m/z: 259 (M
+ H)+. 1H NMR (500 MHz, CDCl3): δ 10.01 (s, 1H), 8.30 (d, J
= 8.6 Hz, 2H), 7.62 (d, J = 8.6 Hz, 2H), 6.81 (s, 1H), 3.11
(sept, J = 6.8 Hz, 1H), 1.23 (d, J = 6.8 Hz, 6H).
4-(5-Isopropyl-3-(spiro[isochromane-1,4′-piperidin]-1′-yl-
methyl)-1H-pyrazol-1-yl)benzoic Acid (25). Spiro-
[isochromane-1,4′-piperidine] (39 mg, 0.19 mmol), 4-(3-
formyl-5-isopropyl-1H-pyrazol-1-yl)benzoic acid (84) (50 mg,
0.19 mmol), and sodium triacetoxyborohydride (82 mg, 0.39
mmol) were combined in DCM (20 mL) according to General
Method 1. Work-up and purification afforded the title
compound (20 mg, 23%). LCMS (ESI) m/z: 446 (M + H)+.
HRMS (ESI) m/z: calcd for C27H32N3O3 [M + H
+], 446.2443;
found, 446.2423. 1H NMR (500 MHz, CDCl3): δ 8.08 (d, J =
8.4 Hz, 2H), 7.30−7.26 (m, 3H), 7.18 (td, J = 7.4, 1.4 Hz, 1H),
7.14 (td, J = 7.4, 1.4 Hz, 1H), 7.09 (d, J = 7.4 Hz, 1H), 6.30 (s,
1H), 4.03 (s, 2H), 3.92 (t, J = 5.5 Hz, 2H), 3.48 (d, J = 10.5 Hz,
2H), 3.09−2.98 (m, 3H), 2.85 (t, J = 5.4 Hz, 2H), 2.66−2.57




zol-1-yl)benzoic Acid (90). Ethyl 5,5-dimethyl-2,4-dioxo-
hexanoate (2.00 g, 9.99 mmol) was dissolved in EtOH (20
mL) and 4-hydrazinobenzoic acid (80) (1.52 g, 9.99 mmol)
was added. The mixture was heated to reflux for 1 h and then
allowed to cool to rt, and the solvent was removed in vacuo.
H2O was added and the product was extracted with EtOAc.
The organics were separated, dried (hydrophobic frit), and
concentrated in vacuo to afford the title compound (3.12 g,
99%). LCMS (ESI) m/z: 317 (M + H)+. 1H NMR (500 MHz,
CD3OD): δ 8.21 (d, J = 8.4 Hz, 2H), 7.52 (d, J = 8.4 Hz, 2H),




bonyl-1H-pyrazol-1-yl)benzoic acid (90) (3.12 g, 9.86 mmol)
was dissolved in DCM (20 mL), and HOBt (1.60 g, 11.84
mmol), EDC.HCl (2.27 g, 11.84 mmol), DIPEA (6.87 mL,
39.45 mmol), and 2-chloroethanamine hydrochloride (1.37 g,
11.84 mmol) were added. The reaction was stirred at rt for 1 h.
The reaction mixture was washed with H2O extracting with
further DCM. The organics were dried (hydrophobic frit) and
the solvent was removed in vacuo to afford an orange oil. The
crude material was purified by flash chromatography (10−50%
EtOAc in heptane) to afford ethyl 5-tert-butyl-1-[4-(2-
chloroethylcarbamoyl)phenyl]-1H-pyrazole-3-carboxylate
(1.76 g, 47%). LCMS (ESI) m/z: 378 (M + H)+. 1H NMR
(400 MHz, CDCl3): δ 7.88 (d, J = 8.6 Hz, 2H), 7.46 (d, J = 8.6
Hz, 2H), 6.90−6.38 (m, 1H), 6.76 (s, 1H), 4.41 (q, J = 7.1 Hz,
2H), 3.85−3.79 (m, 2H), 3.78−3.73 (m, 2H), 1.39 (t, J = 7.1
Hz, 3H), 1.19 (s, 9H). Ethyl 5-tert-butyl-1-[4-(2-
chloroethylcarbamoyl)phenyl]-1H-pyrazole-3-carboxylate
(1.76 g, 4.66 mmol) was dissolved in THF (20 mL) and cooled
to 0 °C. NaH (186 mg, 4.66 mmol) was then added, and the
reaction mixture was stirred at 0 °C for 1 h. H2O was added
carefully to quench the reaction, and the volatiles were removed
in vacuo. The product was extracted with TBME, dried
(hydrophobic frit), and concentrated in vacuo to afford the
title compound (1.00 g, 63%). LCMS (ESI) m/z: 342 (M +
H)+. 1H NMR (400 MHz, CDCl3): δ 8.04 (d, J = 8.6 Hz, 2H),
7.45 (d, J = 8.6 Hz, 2H), 6.76 (s, 1H), 4.48 (t, J = 9.5 Hz, 2H),
4.40 (q, J = 7.1 Hz, 2H), 4.10 (t, J = 9.5 Hz, 2H), 1.38 (t, J = 7.1
Hz, 3H), 1.19 (s, 9H).
5-(tert-Butyl)-1-(4-(4,5-dihydrooxazol-2-yl)phenyl)-1H-
pyrazole-3-carbaldehyde (102). Ethyl 5-tert-butyl-1-[4-(4,5-
dihydrooxazol-2-yl)phenyl]-1H-pyrazole-3-carboxylate (96)
(1.00 g, 2.93 mmol) and DIBAL (1 M in DCM) (6.51 mL,
6.51 mmol) were combined in DCM (5 mL) with MnO2 (2.55
g, 29.29 mmol) added in the second step according to General
Method 5b. Work-up and purification afforded the title
compound (624 mg, 68%). LCMS (ESI) m/z: 298 (M +
H)+. 1H NMR (400 MHz, CDCl3): δ 9.95 (s, 1H), 8.10 (d, J =
8.6 Hz, 2H), 7.47 (d, J = 8.6 Hz, 2H), 6.75 (s, 1H), 4.50 (t, J =
9.5 Hz, 2H), 4.12 (t, J = 9.6 Hz, 2H), 1.20 (s, 9H).
1′-((5-(tert-Butyl)-1-(4-(4,5-dihydrooxazol-2-yl)phenyl)-
1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine]
(107). Spiro[isochromane-1,4′-piperidine] (41 mg, 0.20
mmol), 5-tert-butyl-1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-1H-
pyrazole-3-carbaldehyde (102) (60 mg, 0.20 mmol), and
sodium triacetoxyborohydride (86 mg, 0.40 mmol) were
combined in DCM (4 mL) according to General Method 1.
Work-up and purification afforded the title compound (41 mg,
40%). LCMS (ESI) m/z: 485 (M + H)+. 1H NMR (500 MHz,
CDCl3): δ 8.02 (d, J = 8.3 Hz, 2H), 7.44 (d, J = 8.3 Hz, 2H),
7.22 (d, J = 7.7 Hz, 1H), 7.18 (t, J = 7.7 Hz, 1H), 7.13 (td, J =
7.3 Hz, 1.3, 1H), 7.08 (d, J = 7.3 Hz, 1H), 6.22 (s, 1H), 4.47 (t,
J = 9.6 Hz, 2H), 4.10 (t, J = 9.6 Hz, 2H), 3.90 (t, J = 5.5 Hz,
2H), 3.61 (s, 2H), 2.88−2.80 (m, 4H), 2.50 (t, J = 12.1 Hz,
2H), 2.09 (td, J = 13.1, 4.3 Hz, 2H), 1.90 (d, J = 13.1 Hz, 2H),
1.18 (s, 9H).
4-(5-(tert-Butyl)-3-(spiro[isochromane-1,4′-piperidin]-1′-
ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (26). 1′-[[5-tert-
butyl-1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-1H-pyrazol-3-yl]-
methyl]spiro[isochromane-1,4′-piperidine] (107) (41 mg, 0.08
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mmol) was dissolved in 3 M HCl according to General Method
4. Work-up and purification afforded the title compound (15
mg, 37%). LCMS (ESI) m/z: 459 (M + H)+. HRMS (ESI) m/
z: calcd for C28H34N3O3 [M + H
+], 460.2600; found, 460.2613.
1H NMR (500 MHz, d6-DMSO): δ 8.05 (d, J = 8.3 Hz, 2H),
7.52 (d, J = 8.3 Hz, 2H), 7.22 (d, J = 7.4 Hz, 1H), 7.17 (t, J =
7.4 Hz, 1H), 7.13 (t, J = 7.4 Hz, 1H), 7.09 (J = 7.4 Hz, 1H),
6.25 (s, 1H), 3.85−3.80 (m, 2H), 3.53 (br s, 2H), 2.83−2.71
(m, 4H), 2.47−2.39 (m, 2H), 2.01−1.91 (m, 2H), 1.81 (d, J =
13.1 Hz, 2H), 1.14 (s, 9H).
Synthesis of 4-(5-(Difluoromethyl)-3-(spiro[isochromane-
1,4′-piperidin]-1′-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid
(27) (Scheme 2). 4-(5-(Difluoromethyl)-3-(ethoxycarbonyl)-
1H-pyrazol-1-yl)benzoic Acid (91). Ethyl 5,5-difluoro-2,4-
dioxo-pentanoate (2.5 g, 12.88 mmol) was dissolved in EtOH
(20 mL) and AcOH (5 mL) and 4-hydrazinobenzoic acid (80)
(1.96 g, 12.88 mmol) was added. The reaction was heated to
reflux for 18 h and then allowed to cool to rt, and the solvent
was removed in vacuo. H2O was added, and the product was
extracted with EtOAc, dried (hydrophobic frit), and concen-
trated in vacuo to afford the title compound (4.45 g, 100% in
total as a mixture of isomers) and used in the next step without
further purification.
5-(Difluoromethyl)-1-(4-(4,5-dihydrooxazol-2-yl)phenyl)-
1H-pyrazole-3-carbaldehyde (97). A mixture of 4-[5-(difluor-
omethyl)-3-ethoxycarbonyl-1H-pyrazol-1-yl]benzoic acid and
4-[3-(difluoromethyl)-5-ethoxycarbonyl-1H-pyrazol-1-yl]-
benzoic acid (91) (4.45 g, 14.34 mmol in total as a mixture of
isomers) was dissolved in DCM (50 mL) and HOBt (2.87 g,
21.23 mmol), EDC.HCl (3.30 g, 17.21 mmol), DIPEA (7.49
mL, 43.03 mmol), and 2-chloroethanamine hydrochloride
(2.00 g 17.21 mmol) were added. The reaction was stirred at
rt for 18 h. H2O was added, extracting with further DCM. The
combined organics were dried (hydrophobic frit), and the
solvent was removed in vacuo to afford a dark orange oil. The
crude material was purified by flash chromatography (10−50%
EtOAc in heptane). The second compound to elute was the
desired isomer, ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-5-
(difluoromethyl)-1H-pyrazole-3-carboxylate (470 mg, 9%). 1H
NMR (500 MHz, CDCl3): δ 7.94 (d, J = 8.6 Hz, 2H), 7.65 (d, J
= 8.6 Hz, 2H), 7.27 (s, 1H), 6.65 (t, J = 53.5 Hz, 1H), 4.45 (q, J
= 7.1 Hz, 2H), 3.87−3.81 (m, 2H), 3.79−3.75 (m, 2H), 1.41 (t,
J = 7.1 Hz, 3H). Ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-
5-(difluoromethyl)-1H-pyrazole-3-carboxylate (470 mg, 1.26
mmol) was dissolved in THF (25 mL), cooled to 0 °C, and
NaH (202 mg, 5.06 mmol) was added. The reaction was stirred
for 2 h at 0 °C and then quenched by the dropwise addition of
H2O. The mixture was allowed to warm to rt, and the volatiles
were removed in vacuo. The pH was carefully adjusted to pH 6
using 3 M HCl, and the product was extracted with EtOAc,
dried (hydrophobic frit), and concentrated in vacuo to afford a
yellow oil. The aqueous phase was also concentrated in vacuo
and combined with the material obtained from the EtOAc
extraction to afford the title compound, which was used in the
next step without further purification.
5-(Difluoromethyl)-1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-
pyrazo le -3-carbaldehyde (103 ) . Ethy l 1 -[4-(2-
chloroethylcarbamoyl)phenyl]-5-(difluoromethyl)-1H-pyra-
zole-3-carboxylate (97) and DIBAL (1 M in DCM) (2.77 mL,
2.77 mmol) were combined in DCM (30 mL) with MnO2
(1.20 g, 13.83 mmol) added in the second step according to
General Method 5b. Further, DIBAL (1 M in DCM) (2.77 mL,
2.77 mmol) was needed in this case for reaction completion and
oxidation with MnO2 only required 2 h for completion before
formation of side products. Work-up and purification afforded
the title compound (148 mg, 35%). LCMS (ESI) m/z: 292 (M
+ H)+. 1H NMR (500 MHz, CDCl3): δ 10.07 (s, 1H), 8.14 (d, J
= 8.7 Hz, 2H), 7.62 (d, J = 8.7 Hz, 2H), 6.68 (t, J = 53.5 Hz,
1H), 4.50 (t, J = 9.6 Hz, 2H), 4.12 (t, J = 9.6 Hz, 2H).
1′-((5-(Difluoromethyl)-1-(4-(4,5-dihydrooxazol-2-yl)-
phenyl)-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-pi-
peridine] (108). Spiro[isochromane-1,4′-piperidine] (52 mg,
0.25 mmol), 5-(difluoromethyl)-1-[4-(4,5-dihydrooxazol-2-yl)-
phenyl]-1H-pyrazole-3-carbaldehyde (103) (74 mg, 0.25
mmol), and sodium triacetoxyborohydride (108 mg, 0.51
mmol) were combined in DCM (20 mL) according to General
Method 1. Work-up and purification afforded the title
compound (45 mg, 37%). LCMS (ESI) m/z: 479 (M + H)+.
1H NMR (500 MHz, CDCl3): δ 8.07 (d, J = 8.7 Hz, 2H), 7.58
(d, J = 8.7 Hz, 2H), 7.22−7.16 (m, 2H), 7.16−7.12 (m, 1H),
7.08 (d, J = 7.5 Hz, 1H), 6.80 (s, 1H), 6.66 (t, J = 53.5 Hz, 1H),
4.47 (t, J = 9.6 Hz, 2H), 4.10 (t, J = 9.6 Hz, 2H), 3.90 (t, J = 5.5
Hz, 2H), 3.71 (s, 2H), 2.85−2.80 (m, 4H), 2.53 (t, J = 12.0 Hz,
2H), 2.08 (td, J = 13.4, 4.3 Hz, 2H), 1.91 (d, J = 13.4 Hz, 2H).
4-(5-(Difluoromethyl)-3-(spiro[isochromane-1,4′-piperi-
din]-1′-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (27). 1′-[[5-
(Difluoromethyl)-1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-1H-
pyrazol-3-yl]methyl]spiro[isochromane-1,4′-piperidine] (108)
(45 mg, 0.09 mmol) was dissolved in 3 M HCl (3 mL)
according to General Method 3. Work-up and purification
afforded 4-[5-(difluoromethyl)-3-(spiro[isochromane-1,4′-pi-
peridine]-1′-ylmethyl)-1H-pyrazol-1-yl]benzoic acid (19 mg,
44%). LCMS (ESI) m/z: 454 (M + H)+. HRMS (ESI) m/z:
calcd for C25H26F2N3O3 [M + H
+], 454.1916; found, 454.1929.
1H NMR (500 MHz, CDCl3): δ 8.00 (d, J = 8.3 Hz, 2H), 7.30
(d, J = 8.3 Hz, 2H), 7.23 (d, J = 7.7 Hz, 1H), 7.20−7.13 (m,
2H), 7.09 (d, J = 7.3 Hz, 1H), 6.77 (s, 1H), 6.64 (t, J = 53.5 Hz,
1H), 4.02 (s, 2H), 3.96−3.91 (m, 2H), 3.43 (d, J = 10.0 Hz,
2H), 2.98 (t, J = 11.9 Hz, 2H), 2.88−2.82 (m, 2H), 2.52 (t, J =
13.5 Hz, 2H), 2.03 (d, J = 13.5 Hz, 2H).
Synthesis of 4-(3-(Spiro[isochromane-1,4′-piperidin]-1′-
ylmethyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)benzoic Acid
(28) (Scheme 2). 4-(3-(Ethoxycarbonyl)-5-(trifluoromethyl)-
1H-pyrazol-1-yl)benzoic Acid (92). 4-Hydrazinobenzoic acid
(80) (1.43 g, 9.43 mmol) and ethyl 5,5,5-trifluoro-2,4-dioxo-
pentanoate (2.00 g, 9.43 mmol) were dissolved in EtOH (20
mL) and AcOH (5 mL) according to General Method 3a.
Work-up and purification afforded the title compound, which
was used in the next step with no further purification. LCMS
(ESI) m/z: 329 (M + H)+. 1H NMR (500 MHz, CD3OD): δ
7.95 (d, J = 9.0 Hz, 2H), 7.65 (d, J = 9.0 Hz, 2H), 4.34 (q, J =
7.1 Hz, 2H), 1.37 (t, J = 7.1 Hz, 3H).
Ethyl 1-[4-(4,5-Dihydrooxazol-2-yl)phenyl]-5-(trifluoro-
methyl)-1H-pyrazole-3-carboxylate (98). 4-[3-ethoxycarbon-
yl-5-(trifluoromethyl)-1H-pyrazol-1-yl]benzoic acid (92) (3.97
g, 12.10 mmol) was dissolved in DCM (20 mL), and EDC.HCl
(2.78 g, 14.51 mmol), DIPEA (6.25 mg, 48.38 mmol), HOBt
(1.96 g, 14.51 mmol), and 2-chloroethanamine hydrochloride
(1.68 g, 14.51 mmol) were added. The reaction was stirred at rt
overnight. H2O was then added and the mixture was passed
through a hydrophobic frit. The solvent was removed in vacuo
to afford a dark orange oil. The crude material was purified by
flash chromatography (10−50% EtOAc in heptane). The
second fraction to elute afforded the desired isomer, ethyl 1-[4-
(2-chloroethylcarbamoyl)phenyl]-5-(trifluoromethyl)-1H-pyr-
azole-3-carboxylate (467 mg, 10%). LCMS (ESI) m/z: 390 (M
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+ H)+. 1H NMR (500 MHz, CDCl3): δ 7.42 (d, J = 9.0 Hz,
2H), 7.35 (d, J = 9.0 Hz, 2H), 4.33 (q, J = 7.1 Hz, 2H), 3.67−
3.58 (m, 4H), 1.36 (t, J = 7.1 Hz, 3H). Ethyl 1-[4-(2-
chloroethylcarbamoyl)phenyl]-5-(trifluoromethyl)-1H-pyra-
zole-3-carboxylate (467 mg, 1.20 mmol) was dissolved in THF
(25 mL) and cooled to 0 °C. Sodium hydride (197 mg, 4.92
mmol) was added, and the reaction was stirred at 0 °C for 1 h,
allowed to warm to rt for 2 h, and then heated to reflux for 1 h.
The mixture was allowed to cool to rt and was quenched with
H2O dropwise. The reaction mixture was concentrated in vacuo
to afford the title compound, which was used without further
purification.
1-[4-(4,5-Dihydrooxazol-2-yl)phenyl]-5-(trifluoromethyl)-
1H-pyrazole-3-carbaldehyde (104). Ethyl 1-[4-(4,5-dihy-
drooxazol-2-yl)phenyl]-5-(trifluoromethyl)-1H-pyrazole-3-car-
boxylate (98) and DIBAL (1 M in DCM) (3.00 mL, 3.00
mmol) were combined in DCM (50 mL) according to General
Method 6b. Further DIBAL (1 M in DCM) (1.20 mL, 1.20
mmol) was added in this case, but the reaction was not pushed
to completion. LiAlH4 (1.20 mL, 1.20 mmol) was therefore
added and the reaction was allowed to warm to rt for 18 h
before adding further LiAlH4 (1.20 mL, 1.20 mmol) and
stirring at rt for 2 h. MnO2 (1.04 g, 11.99 mmol) was added in
the second step according to General Method 6b. Work-up and
purification afforded the title compound as a colorless oil (45
mg, 12%). LCMS (ESI) m/z: 310 (M + H)+. 1H NMR (500
MHz, CDCl3): δ 10.06 (s, 1H), 8.13 (d, J = 8.7 Hz, 2H), 7.59
(d, J = 8.7 Hz, 2H), 5.30 (s, 1H), 4.50 (t, J = 9.6 Hz, 2H), 4.12
(t, J = 9.6 Hz, 2H).
1′-((1-(4-(4,5-Dihydrooxazol-2-yl)phenyl)-5-(trifluoro-
methyl)-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-pi-
peridine] (109). Spiro[isochromane-1,4′-piperidine] (30 mg,
0.15 mmol), 1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-5-(trifluor-
omethyl)-1H-pyrazole-3-carbaldehyde (104) (45 mg, 0.15
mmol), and sodium triacetoxyborohydride (62 mg, 0.29
mmol) were combined in DCM (20 mL) according to General
Method 1. Work-up and purification afforded the title
compound (32 mg, 44%). LCMS (ESI) m/z: 497 (M + H)+.
1H NMR (500 MHz, CDCl3): δ 8.08−8.04 (m, 2H), 7.56 (d, J
= 8.6 Hz, 2H), 7.22−7.17 (m, 2H), 7.16−7.13 (m, 1H), 7.09
(d, J = 7.5 Hz, 1H), 6.87 (s, 1H), 4.47 (t, J = 9.6 Hz, 2H), 4.10
(t, J = 9.6 Hz, 2H), 3.90 (t, J = 5.5 Hz, 2H), 3.70 (s, 2H), 2.85−
2.78 (m, 2H), 2.54 (t, J = 11.7 Hz, 2H), 2.08 (td, J = 13.2, 3.7
Hz, 2H), 1.92 (d, J = 13.7 Hz, 2H).
4-(3-(Spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-5-
(trifluoromethyl)-1H-pyrazol-1-yl)benzoic Acid (28). 1′-[[1-
[4-(4,5-Dihydrooxazol-2-yl)phenyl]-5-(trifluoromethyl)-1H-
pyrazol-3-yl]methyl]spiro[isochromane-1,4′-piperidine] (109)
(32 mg, 0.06 mmol) was dissolved in 3 M HCl according to
General Method 4. Work-up afforded no product. The aqueous
phase was concentrated in vacuo and purified by preparative
HPLC (XBridge column, 0.1% NH4OH modifier) to afford the
title compound (5 mg, 66%). LCMS (ESI) m/z: 472 (M + H)+.
HRMS (ESI) m/z: calcd for C25H25F3N3O3 [M + H
+],
472.1848; found, 472.1851. 1H NMR (500 MHz, CDCl3): δ
8.46 (d, J = 8.5 Hz, 2H), 7.95 (d, J = 8.5 Hz, 2H), 7.74 (t, J =
53.5 Hz, 1H), 7.73 (t, J = 7.2 Hz, 1H), 7.43 (td, J = 8.7, 2.7 Hz,
1H), 7.38 (dd, J = 9.7, 2.7 Hz, 1H), 4.25 (t, J = 5.5 Hz, 2H),
4.03 (s, 2H), 3.19 (t, J = 5.5 Hz, 2H), 3.15 (d, J = 10.5 Hz, 2H),





(82). 1-Cyclopropylethanone (11.8 mL, 119 mmol) was
dissolved in toluene (100 mL) and cooled to 0 °C. NaH
(60% dispersion, 9.5 g, 238 mmol) was added portionwise and
stirred at 0 °C for 30 min. Ethyl 2,2-diethoxyacetate (21 mL,
119 mmol) was added dropwise, and the reaction was stirred at
0 °C for 2 h, after which the reaction was allowed to warm to rt
and left to stir for 1 h. The reaction was cooled to 0 °C and H2O
was added dropwise until the reaction was quenched, followed
by 3 M HCl solution, dropwise, until the solution was pH 2.
NH4Cl (saturated solution) was added to neutralize, and the
aqueous phase was extracted with EtOAc. The combined
organic extracts were dried over Na2SO4 and concentrated in
vacuo to afford the title compound, which was used in the next
step with no further purification.
4-(5-Cyclopropyl-3-formyl-1H-pyrazol-1-yl)benzoic Acid
(85). 1-Cyclopropyl-4,4-diethoxy-butane-1,3-dione (82) (995
mg, 4.64 mmol) was dissolved in EtOH (2 mL) and H2O (2
mL), and 4-hydrazinobenzoic acid (642 mg, 4.22 mmol) was
added. The reaction mixture was stirred at 35 °C for 18 h and
then allowed to cool to rt and concentrated in vacuo to afford an
orange solid. The solid was triturated with Et2O, and the yellow
solid filtered and dried to afford 4-(5-cyclopropyl-3-formyl-1H-
pyrazol-1-yl)benzoic acid (443 mg, 39%). LCMS (ESI) m/z:
257 (M + H)+. 1H NMR (500 MHz, d6-DMSO): δ 13.17 (br s,
1H), 9.92 (s, 1H), 8.16−8.12 (m, 2H), 7.89−7.86 (m, 2H),
6.70 (s, 1H), 1.96−1.89 (m, 1H), 1.04−0.97 (m, 2H), 0.87−
0.82 (m, 2H).
4-(5-Cyclopropyl-3-(spiro[isochromane-1,4′-piperidin]-1′-
ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (27). Spiro-
[isochromane-1,4′-piperidine] (10.73 g, 52.80 mmol), 4-(5-
cyclopropyl-3-formyl-1H-pyrazol-1-yl)benzoic acid (85)
(12.30 g, 48.00 mmol), and sodium triacetoxyborohydride
(20.35 g, 95.99 mmol) were combined in DCM (4 mL)
according to General Method 1. After work-up, the crude
material was passed through a silica plug (washing with 0−30%
MeOH in EtOAc) to afford 4-[5-cyclopropyl-3-(spiro-
[isochromane-1,4′-piperidine]-1′-ylmethyl)-1H-pyrazol-1-yl]-
benzoic acid (15.00 g, 70%). LCMS (ESI) m/z: 444 (M + H)+.
1H NMR (400 MHz, DMSO-d6): δ 12.74 (br s, 1H), 8.09−8.05
(m, 2H), 7.83−7.79 (m, 2H), 7.27−7.06 (m, 4H), 6.17 (s, 1H),
3.82 (t, J = 5.4 Hz, 2H), 3.51 (s, 2H), 2.79−2.65 (m, 4H), 2.40
(t, J = 11.9 Hz, 2H), 1.98−1.89 (m, 4H), 1.78 (d, J = 13.2 Hz,
2H), 1.04−0.99 (m, 2H), 0.80−0.75 (m, 2H).
Synthesis of 4-(5-Cyclopropyl-3-(spiro[isochromane-1,4′-
piperidin]-1′-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (29)
Hydrochloride (Scheme 2). 4-[5-Cyclopropyl-3-(spiro-
[isochromane-1,4′-piperidine]-1′-ylmethyl)-1H-pyrazol-1-yl]-
benzoic acid (29) (35 g, 79 mmol) was suspended in MeOH
(50 mL) and 4 M HCl in dioxane (49 mL, 197 mmol) was
added. The suspended solids went into the solution and the
reaction was stirred at rt for 2 h. The precipitated solid was
filtered and washed with a small amount of cold MeOH and
dried. The solid was then recrystallized from 10% H2O in EtOH
(∼1.70 L) to afford the title compound as the HCl salt (17 g,
44%). LCMS (ESI) m/z: 444 (M + H)+. HRMS (ESI) m/z:
calcd for C27H30N3O3 [M + H
+], 444.2287; found, 444.2278.
1H NMR (400 MHz, DMSO-d6): δ 13.21 (br s, 1H), 10.58 (br
s, 1H), 8.14−8.11 (m, 2H), 7.87−7.84 (m, 2H), 7.27−7.12 (m,
4H), 6.48 (s, 1H), 4.38 (s, 2H), 3.87 (t, J = 5.3 Hz, 2H), 3.43−
3.37 (m, 2H), 3.30−3.20 (m, 2H), 2.78 (t, J = 5.3 Hz, 2H),
2.41−2.33 (m, 2H), 2.06−1.95 (m, 3H), 1.08−1.03 (m, 2H),
0.79−0.75 (m, 2H).
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(85). To a solution of 1-cyclobutylethanone (5 g, 51 mmol)
in toluene (43 mL) cooled to 0 °C was added NaH (60%
dispersion, 4 g, 102 mmol) portionwise. The reaction was
stirred at 0 °C for 10 min before the dropwise addition of ethyl
2,2-diethoxyacetate (9.1 mL, 51 mmol). The reaction was
stirred at 0 °C for further 10 min before being allowed to warm
to rt. After 1 h, the reaction started to exotherm, and the
reaction was cooled to 0 °C for an additional 1 h. Water was
added dropwise until the reaction was quenched, followed by 3
M HCl until the solution was pH 4. The organics were
extracted with DCM, passed through a hydrophobic frit, and
concentrated in vacuo to afford the title compound, which was
used in the next step with no further purification.
4-(5-Cyclobutyl-3-formyl-1H-pyrazol-1-yl)benzoic Acid
(86). 1-Cyclobutyl-4,4-diethoxy-butane-1,3-dione (83) (4.80
g, 21.03 mmol) was dissolved in EtOH (2 mL) and H2O (2
mL), and 4-hydrazinobenzoic acid (3.20 g, 21.03 mmol) were
added. The mixture was stirred at 35 °C for 18 and then
allowed to cool to rt and concentrated in vacuo to afford a
mixture of 4-(3-cyclobutyl-5-formyl-pyrazol-1-yl)benzoic acid
and 4-(5-cyclobutyl-3-formyl-1H-pyrazol-1-yl)benzoic acid
(5.15 g, 86% total). No attempt was made to separate isomers
at this stage, and the mixture was used without further
purification. LCMS (ESI) m/z: 271 (M + H)+. 1H NMR (500
MHz, CDCl3): δ 11.85 (br s, 1H), 10.04 (s, 1H), 8.29 (d, J =
8.6 Hz, 2H), 7.60 (d, J = 8.6 Hz, 2H), 6.91 (s, 1H), 3.57 (quint,
J = 8.6 Hz, 1H), 2.49−1.90 (m, 6H) (desired isomer reported).
4-(5-Cyclobutyl-3-formyl-1H-pyrazol-1-yl)benzoic acid and 4-
(3-cyclobutyl-5-formyl-pyrazol-1-yl)benzoic acid (5.15 g, 19.05
mmol total as a mixture of isomers) were dissolved in tert-
butanol (20 mL). DMAP (6.99 g, 57.16 mmol) and EDC.HCl
(7.31 g, 38.11 mmol) were added. The mixture was heated to
reflux for 2 h and then allowed to cool to rt and poured into
H2O. The product was extracted with EtOAc, dried (hydro-
phobic frit), and concentrated in vacuo. The crude material was
purified by flash chromatography (0−20% EtOAc in heptane)
to afford the transesterified methyl ester, methyl 4-(5-
cyclobutyl-3-formyl-1H-pyrazol-1-yl)benzoate (641 mg, 12%).
LCMS (ESI) m/z: 285 (M + H)+. 1H NMR (500 MHz,
CDCl3): δ 9.87 (s, 1H), 8.17 (d, J = 8.6 Hz, 2H), 7.58 (d, J =
8.6 Hz, 2H), 7.02 (s, 1H), 3.66 (quint, J = 8.6 Hz, 1H), 2.45−
2.37 (m, 2H), 2.32−2.23 (m, 2H), 2.13−2.02 (m, 1H), 2.01−
1.91 (m, 1H). Methyl 4-(5-cyclobutyl-3-formyl-1H-pyrazol-1-
yl)benzoate (641 mg, 2.25 mmol) was dissolved in MeOH, and
2 M NaOH (11.27 mL, 22.55 mmol) was added. The mixture
was stirred at rt for 2 h and then neutralized with 3 M HCl and
extracted with DCM. The organics were separated, dried
(hydrophobic frit), and concentrated in vacuo to afford the title
compound (632 mg, 100%). LCMS (ESI) m/z: 271 (M + H)+.
1H NMR (500 MHz, CDCl3): δ 10.02 (s, 1H), 8.27 (d, J = 8.6
Hz, 2H), 7.59 (d, J = 8.6 Hz, 2H), 6.89 (s, 1H), 3.56 (quint, J =
8.4 Hz, 1H), 2.39−2.29 (m, 2H), 2.19 (quint, J = 9.2 Hz, 2H),
2.00 (quint, 9.2 Hz, 1H), 1.98−1.90 (m, 1H).
4-(5-Cyclobutyl-3-(spiro[isochromane-1,4′-piperidin]-1′-
ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (30). Spiro-
[isochromane-1,4′-piperidine] (38 mg, 0.19 mmol), 4-(5-
cyclobutyl-3-formyl-1H-pyrazol-1-yl)benzoic acid (86) (50
mg, 0.19 mmol), and sodium triacetoxyborohydride (78 mg,
0.37 mmol) were combined in DCM (20 mL) according to
General Method 1. Work-up and purification afforded the title
compound (16 mg, 18%). LCMS (ESI) m/z: 458 (M + H)+.
HRMS (ESI) m/z: calcd for C28H32N3O3 [M + H
+], 458.2433;
found, 458.2438. 1H NMR (500 MHz, CDCl3): δ 8.03 (d, J =
8.4 Hz, 2H), 7.29 (d, J = 7.8 Hz, 1H), 7.22 (d, J = 8.4 Hz, 2H),
7.18 (td, J = 7.3, 1.3 Hz, 1H), 6.40 (s, 1H), 4.01 (s, 2H), 3.93 (t,
J = 5.5 Hz, 2H), 3.52−3.44 (m, 3H), 3.00 (t, J = 12.2 Hz, 2H),
2.85 (t, J = 5.4 Hz, 2H), 2.60 (t, J = 13.7 Hz, 2H), 2.28−1.89




(Scheme 3). Methyl 1-(4-Bromophenyl)-5-hydroxy-1H-pyr-
azole-3-carboxylate (110). Dimethyl but-2-ynedioate (61)
(3.29 mL, 26.73 mmol) was dissolved in Et2O (50 mL), and a
suspension of 4-bromophenylhydrazine (5.00 g, 26.73 mmol)
in Et2O (50 mL) was added slowly over 30 min. The reaction
mixture was stirred at rt for 1 h and then concentrated in vacuo.
The residue was redissolved in MeOH (100 mL), NaOMe
(25% wt) (23 mL, 106.93 mmol) was added, and the reaction
mixture was stirred at rt for 18 h. The mixture was concentrated
in vacuo, and then 6 M HCl (10 mL) was added. The resulting
precipitate was filtered and washed with DCM and Et2O. The
solid was redissolved in MeOH, 10 drops of H2SO4 were added,
and the mixture was heated to reflux for 4 h and then allowed to
cool to rt. The resulting precipitate was filtered and washed
with ice-cold MeOH and air-dried to afford the title compound
(5.65 g, 64%). LCMS (ESI) m/z: 297/299 (M + H)+. 1H NMR
(400 MHz, DMSO-d6): δ 12.46 (br s, 1H), 7.76−7.67 (m, 4H),
5.99 (s, 1H), 3.37 (br s, 1H).
Methyl 1-(4-Bromophenyl)-5-methoxy-1H-pyrazole-3-car-
boxylate (114). Methyl 1-(4-bromophenyl)-5-hydroxy-1H-
pyrazole-3-carboxylate (110) (250 mg, 0.84 mmol) was
dissolved in DMF (5 mL) and K2CO3 (174 mg, 1.26 mmol)
was added. The reaction mixture was cooled to 0 °C, and
iodomethane (0.06 mL, 0.93 mmol) was added dropwise. The
reaction was allowed to warm to rt and stirred at this
temperature for 2 h. EtOAc and H2O were added, and the
organics were separated and washed with H20, NaHCO3
(saturated solution), and brine before concentrating in vacuo.
The crude material was purified by flash chromatography (10−
20% EtOAc in heptane) to afford the title compound (162 mg,
62%). LCMS (ESI) m/z: 311/313 (M + H)+. 1H NMR (400
MHz, CDCl3): δ 7.63 (d, J = 8.9 Hz, 2H), 7.56 (d, J = 8.9 Hz,
2H), 6.23 (s, 1H), 3.99 (s, 3H), 3.94 (s, 3H).
1-(4-Bromophenyl)-5-methoxy-1H-pyrazole-3-carbalde-
hyde (118). Methyl 1-(4-bromophenyl)-5-methoxy-1H-pyra-
zole-3-carboxylate (114) (162 mg, 0.52 mmol) and DIBAL (1
M in DCM) (0.52 mL, 0.52 mmol) were combined in THF (5
mL) according to General Method 5b. Further DIBAL (1 M in
DCM) (0.52 mL, 0.52 mmol) was added in this case to push
the reaction to completion. MnO2 (453 mg, 5.21 mmol) was
added in the second step according to General Method 5b.
Work-up and purification afforded the title compound (146 mg,
100%). LCMS (ESI) m/z: 281/283 (M + H)+. 1H NMR (500
MHz, CDCl3): δ 9.88 (s, 1H), 7.66 (d, J = 9.0 Hz, 2H), 7.60 (d,
J = 9.0 Hz, 2H), 6.18 (s, 1H), 4.00 (s, 3H).
1′-((1-(4-Bromophenyl)-5-methoxy-1H-pyrazol-3-yl)-
methyl)spiro[isochromane-1,4′-piperidine] (122). Spiro-
[isochromane-1,4′-piperidine] (181 mg, 0.89 mmol), 1-(4-
bromophenyl)-5-methoxy-1H-pyrazole-3-carbaldehyde (118)
(250 mg, 0.89 mmol), and sodium triacetoxyborohydride
(377 mg, 1.78 mmol) were combined in DCM (5 mL)
according to General Method 1. Work-up and purification
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afforded the title compound (287 mg, 68%). LCMS (ESI) m/z:
468/470 (M + H)+. 1H NMR (500 MHz, CDCl3): δ 7.61 (d, J
= 8.9 Hz, 2H), 7.52 (d, J = 8.9 Hz, 2H), 7.24−7.18 (m, 2H),
7.17−7.13 (m, 1H), 7.08 (s, J = 7.4 Hz, 1H), 5.85 (s, 1H), 3.96
(s, 3H), 3.88 (t, J = 5.5 Hz, 2H), 3.81−3.70 (m, 2H), 3.08−
2.96 (m, 2H), 2.82 (t, J = 5.5 Hz, 2H), 2.77−2.65 (m, 2H),
2.31−2.14 (m, 2H), 1.94 (d, J = 13.8 Hz, 2H).
4-(5-Methoxy-3-(spiro[isochromane-1,4′-piperidin]-1′-yl-
methyl)-1H-pyrazol-1-yl)benzoic Acid (31). 1′-[[1-(4-Bromo-
pheny l) -5 -methoxy-1H -pyrazo l -3 -y l ]methy l ] sp i ro-
[isochromane-1,4′-piperidine] (122) (58 mg, 0.12 mmol), N-
formylsaccharin (31 mg, 0.15 mL), Pd(OAc)2 (0.8 mg, 0.004
mmol), Xantphos (3 mg, 0.006 mmol), and KF (18 mg, 0.31
mmol) were combined in DMF (1 mL) according to General
Method 5. Work-up and purification afforded the title
compound (11 mg, 21%). LCMS (ESI) m/z: 434 (M + H)+.
HRMS (ESI) m/z: calcd for C25H28N3O4 [M + H
+], 434.2080;
found, 434.2077. 1H NMR (400 MHz, CDCl3): δ 8.05 (d, J =
8.6 Hz, 2H), 7.67 (d, J = 8.6 Hz, 2H), 7.23 (d, J = 7.9 Hz, 1H),
7.21−7.11 (m, 2H), 7.08 (d, J = 7.4 Hz, 1H), 5.85 (s, 1H),
3.94−3.88 (m, 7H), 3.35 (d, J = 10.8 Hz, 2H), 2.92 (t, J = 11.9
Hz, 2H), 2.84 (t, J = 5.3 Hz, 2H), 2.46 (t, J = 13.0 Hz, 2H), 2.00
(d, J = 14.0 Hz, 2H.
Synthesis of 4-(5-Ethoxy-3-(spiro[isochromane-1,4′-piper-
idin]-1′-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (32)
(Scheme 3). Methyl 1-(4-Bromophenyl)-5-ethoxy-1H-pyra-
zole-3-carboxylate (115). Methyl 1-(4-bromophenyl)-5-hy-
droxy-1H-pyrazole-3-carboxylate (110) (500 mg, 1.68 mmol)
was dissolved in DMF (5 mL) and K2CO3 (349 mg, 2.52
mmol) was added. The reaction mixture was cooled to 0 °C,
and iodoethane (0.13 mL, 1.68 mmol) was added dropwise.
The reaction was allowed to warm to rt and stirred for 2 h.
EtOAc and H2O were added. The organics were separated and
washed with H20, NaHCO3 (saturated aqueous solution), and
brine and concentrated in vacuo. The crude material was
purified by flash chromatography (10−20% EtOAc in heptane)
to afford the title compound (369 mg, 67%). LCMS (ESI)m/z:
369/371 (M + H)+. 1H NMR (400 MHz, CDCl3): δ 7.65 (d, J
= 8.9 Hz, 2H), 7.56 (d, J = 8.9 Hz, 2H), 6.20 (s, 1H), 4.22 (q, J
= 7.1 Hz, 2H), 3.93 (s, 3H), 1.46 (t, J = 7.1 Hz, 3H).
1-(4-Bromophenyl)-5-ethoxy-1H-pyrazole-3-carbalde-
hyde (119).Methyl 1-(4-bromophenyl)-5-ethoxy-1H-pyrazole-
3-carboxylate (115) (369 mg, 1.13 mmol) and DIBAL (1.36
mL, 1.36 mmol) were combined in THF (5 mL) according to
General Method 6b. Further, DIBAL (2.72 mL, 2.72 mmol)
was added in this case to push the reaction to completion.
MnO2 (987 mg, 11.45 mmol) was added in the second step
according to General Method 6b. Work-up and purification
afforded the title compound (164 mg, 47%). LCMS (ESI) m/z:
295/297 (M + H)+. 1H NMR (400 MHz, CDCl3): δ 9.88 (s,
1H), 7.68 (d, J = 9.0 Hz, 2H), 7.60 (d, J = 9.0 Hz, 2H), 6.15 (s,
1H), 4.23 (q, J = 7.1 Hz, 2H), 1.48 (t, J = 7.1 Hz, 2H).
1′-((1-(4-Bromophenyl)-5-ethoxy-1H-pyrazol-3-yl)-
methyl)spiro[isochromane-1,4′-piperidine] (123). Spiro-
[isochromane-1,4′-piperidine] (56 mg, 0.28 mmol), 1-(4-
bromophenyl)-5-ethoxy-1H-pyrazole-3-carbaldehyde (119)
(82 mg, 0.28 mmol), and sodium triacetoxyborohydride (118
mg, 0.56 mmol) were combined in DCM (10 mL) according to
General Method 1. Work-up followed by flash chromatography
(10−100% EtOAc in heptane) afforded the title compound (96
mg, 72%). LCMS (ESI) m/z: 482/484 (M + H)+. 1H NMR
(400 MHz, CDCl3): δ 7.64 (d, J = 8.9 Hz, 2H), 7.51 (d, J = 8.9
Hz, 2H), 7.23−7.12 (m, 3H), 7.08 (d, J = 7.5 Hz, 1H), 5.76 (s,
1H), 4.18 (q, J = 7.1 Hz, 2H), 3.89 (t, J = 5.5 Hz, 2H), 3.65 (s,
2H), 2.96−2.87 (m, 2H), 2.82 (t, J = 5.5 Hz, 2H), 2.66−2.54
(m, 2H), 2.20−2.07 (m, 2H), 1.91 (d, J = 14.0 Hz, 2H), 1.46 (t,
J = 7.1 Hz, 3H).
4-(5-Ethoxy-3-(spiro[isochromane-1,4′-piperidin]-1′-yl-
methyl)-1H-pyrazol-1-yl)benzoic Acid (32). 1′-[[1-(4-Bromo-
phenyl)-5-ethoxy-1H-pyrazol-3-yl]methyl]spiro[isochromane-
1,4′-piperidine] (123) (96 mg, 0.20 mmol), Pd(OAc)2 (1 mg,
0.01 mmol), Xantphos (5 mg, 0.01 mmol), KF (29 mg, 0.50
mmol), and N-formylsaccharin (50 mg, 0.24 mmol) were
combined in DMF (1 mL) according to General Method 5.
Work-up and purification afforded the title compound (10 mg,
11%). LCMS (ESI) m/z: 448 (M + H)+. HRMS (ESI) m/z:
calcd for C26H30N3O4 [M + H]
+: 448.2236; found, 448.2249.
1H NMR (400 MHz, CDCl3): δ 8.07 (d, J = 8.6 Hz, 2H), 7.70
(d, J = 8.6 Hz, 2H), 7.25−7.21 (m, 1H), 7.20−7.11 (m, 2H),
7.08 (d, J = 7.5 Hz, 1H), 5.84 (s, 1H), 4.11 (q, J = 7.1 Hz, 2H),
3.94−3.88 (m, 2H), 3.33 (d, J = 10.4 Hz, 2H), 2.92 (t, J = 12.1
Hz, 2H), 2.84 (t, J = 5.5 Hz, 2H), 2.45 (t, J = 13.4 Hz, 2H), 2.00
(d, J = 14.0 Hz, 2H), 1.41 (t, J = 7.1 Hz, 3H).
Synthesis of 4-[5-Pyrrolidin-1-yl-3-(spiro[isochromane-
1,4′-piperidine]-1′-ylmethyl)pyrazol-1-yl]benzoic Acid (33)
(Scheme 3). Methyl 1-(4-Bromophenyl)-5-chloro-4-formyl-
1H-pyrazole-3-carboxylate (111). POCl3 (2 mL, 1.68 mmol)
was added cautiously to methyl 1-(4-bromophenyl)-5-hydroxy-
pyrazole-3-carboxylate (120) (500 mg, 1.68 mmol), and then
DMF (0.16 mL, 2.02 mmol) was added. The reaction mixture
was heated to 100 °C for 2 h and then allowed to cool to rt,
added to a H2O/ice mixture, and stirred for 1 h. The resulting
precipitate was filtered, washed with H2O and heptane, and air-
dried. The solid was dissolved in DCM and passed through a
hydrophobic frit. The filtrate was concentrated in vacuo to
afford the title compound as a beige solid (450 mg, 70%). 1H
NMR (400 MHz, CDCl3): δ 10.54 (s, 1H), 7.72−7.69 (m,
2H), 7.49−7.46 (m, 2H), 4.05 (s, 3H).
Methyl 1-(4-Bromophenyl)-4-formyl-5-(pyrrolidin-1-yl)-
1H-pyrazole-3-carboxylate (112). Methyl 1-(4-bromophen-
yl)-5-chloro-4-formyl-pyrazole-3-carboxylate (111) (600 mg,
1.75 mmol) and pyrrolidine (248 mg, 3.49 mmol) were taken
up in DMF (3 mL) before the addition of K2CO3 (483 mg, 3.49
mmol). The reaction mixture was heated to 120 °C in the
microwave for 1 h and then quenched with water. The product
was extracted with DCM, dried (hydrophobic frit), and
concentrated in vacuo. The crude material was purified by
flash chromatography (0−80% EtOAc in heptane) to afford the
title compound (270 mg, 39%). LCMS (ESI)m/z: 378, 380 (M
+ H)+. 1H NMR (400 MHz, CDCl3): δ 10.37 (s, 1H), 7.62−
7.58 (m, 2H), 7.38−7.45 (m, 2H), 3.97 (s, 3H), 3.26−3.22 (m,
4H), 1.89−1.86 (m, 4H).
Methyl 1-(4-Bromophenyl)-5-(pyrrolidin-1-yl)-1H-pyra-
zole-3-carboxylate (116). To a solution of p-TsOH (24 mg,
0.13 mmol) in MeOH (3 mL) was added methyl 1-(4-
bromophenyl)-4-formyl-5-pyrrolidin-1-yl-pyrazole-3-carboxy-
late (112) (220 mg, 0.58 mmol). The reaction mixture was
heated to 120 °C in the microwave for 1 h. The reaction was
concentrated in vacuo to afford the title compound, which was
used in the next step with no further purification (200 mg,
77%). LCMS (ESI) m/z: 350, 352 (M + H)+. 1H NMR (400
MHz, CDCl3): δ 7.59−7.50 (m, 4H), 6.21 (s, 1H), 3.92 (s,
3H), 3.00 (m, 4H), 1.88−1.85 (m, 4H).
1-(4-Bromophenyl)-5-(pyrrolidin-1-yl)-1H-pyrazole-3-car-
baldehyde (120). Methyl 1-(4-bromophenyl)-5-pyrrolidin-1-
yl-pyrazole-3-carboxylate (116) (200 mg, 0.57 mmol) was
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dissolved in DCM (10 mL) and cooled to −78 °C under N2.
DIBAL (1 M in DCM, 1.43 mL, 1.43 mmol) was then added
dropwise over 20 min and the reaction was stirred for a further
1 h at −78 °C. The reaction was quenched with 5 mL of 1:1
MeOH/H2O, allowed to warm up to rt, and then passed
through a hydrophobic frit and concentrated in vacuo to the title
compound, which was used in the next step with no further
purification (166 mg, 81%). LCMS (ESI) m/z: 320, 322 (M +
H)+.1H NMR (400 MHz, CDCl3): δ 9.87 (s, 1H), 7.63−7.59




[isochromane-1,4′-piperidine] (50 mg, 0.25 mmol), 1-(4-
bromophenyl)-5-pyrrolidin-1-yl-1H-pyrazole-3-carbaldehyde
(120) (88 mg, 0.25 mmol), and sodium triacetoxyborohydride
(104 mg, 0.49 mmol) were combined in DCM (3 mL)
according to General Method 1. Work-up followed by
purification afforded the title compound (62 mg, 47%).
HRMS (ESI) m/z: calcd for C27H32BrN4O [M + H]
+:
509.1670; found, 509.1756. 1H NMR (400 MHz, CHCl3): δ
7.54−7.53 (m, 4H), 7.24−7.08 (m, 4H), 5.75 (s, 1H), 3.91 (t, J
= 5.5 Hz, 2H), 3.58 (s, 2H), 3.00 (t, J = 6.6 Hz, 4H), 2.89−2.81
(m, 4H), 2.56−2.48 (m, 2H), 2.14−2.01 (m, 2H), 1.93−1.84
(m, 6H).
4-[5-Pyrrolidin-1-yl-3-(spiro[isochromane-1,4′-piperi-
dine]-1′-ylmethyl)pyrazol-1-yl]benzoic Acid (33). 1′-[[1-(4-
Bromophenyl)-5-pyrrolidin-1-yl-1H-pyrazol-3-yl]methyl]spiro-
[isochromane-1,4′-piperidine] (124) (62 mg, 0.12 mmol), N-
formylsaccharin (31 mg, 0.15 mmol), Pd(OAc)2 (0.8 mg, 0.004
mmol), Xantphos (3 mg, 0.006 mmol), and KF (18 mg, 0.31
mmol) were combined in DMF (2 mL) according to General
Method 5. Work-up and purification afforded the title
compound (4 mg, 6%). HRMS (ESI) m/z: calcd for
C28H33N4O3 [M + H]
+: 473.2547; found, 473.2545. 1H
NMR (400 MHz, D6-DMSO): δ 8.02 (d, J = 8.8 Hz, 2H),
7.71 (d, J = 8.7 Hz, 2H), 7.22−7.07 (m, 4H), 5.83 (s, 1H), 3.81
(dd, J = 5.5, 5.5 Hz, 2H), 3.44 (s, 2H), 3.33 (s, 1H), 2.96 (dd, J
= 6.4, 6.4 Hz, 4H), 2.73 (dd, J = 5.4, 5.4 Hz, 4H), 2.42−2.33
(m, 2H), 1.97−1.89 (m, 2H), 1.84−1.76 (m, 6H).
Synthesis of 4-(5-Morpholino-3-(spiro[isochromane-1,4′-
piperidin]-1′-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (34)
(Scheme 3). Methyl 1-(4-Bromophenyl)-4-formyl-5-morpho-
lino-1H-pyrazole-3-carboxylate (113). Methyl 1-(4-bromo-
phenyl)-5-chloro-4-formyl-1H-pyrazole-3-carboxylate (111)
(100 mg, 0.29 mmol) and K2CO3 (80 mg, 0.58 mmol) were
mixed in DMF (1 mL) and morpholine (0.05 mL, 0.58 mmol)
was added. The reaction mixture was heated to 120 °C in the
microwave for 1 h and then quenched with H2O and extracted
with DCM. The organics were concentrated in vacuo, and the
crude material was purified by flash chromatography (0−80%
EtOAc in heptane) to afford the title compound (37 mg, 31%).
1H NMR (400 MHz, CDCl3): δ 10.44 (s, 1H), 7.66 (d, J = 8.8
Hz, 2H), 7.42 (d, J = 8.7 Hz, 2H), 3.99 (s, 3H), 3.73−3.69 (m,
4H), 3.11 (dd, J = 4.6, 4.6 Hz, 4H).
Methyl 1-(4-Bromophenyl)-5-morpholino-1H-pyrazole-3-
carboxylate (117). Methyl 1-(4-bromophenyl)-4-formyl-5-
morpholino-1H-pyrazole-3-carboxylate (113) (250 mg, 0.63
mmol) was mixed in MeOH (5 mL) and p-TsOH (24 mg, 0.13
mmol) was added. The reaction mixture was heated to 120 °C
in the microwave for 1 h and then concentrated in vacuo to
afford the title compound (200 mg, 78%). 1H NMR (400 MHz,
CDCl3): δ 7.73 (2H, d, J = 8.8 Hz), 7.61 (2H, d, J = 8.9 Hz),
6.47 (1H, s), 3.95 (3H, s), 3.77−3.73 (4H, m), 2.92−2.89 (4H,
m).
1-(4-Bromophenyl)-5-morpholino-1H-pyrazole-3-carbal-
dehyde (121). Methyl 1-(4-bromophenyl)-5-morpholino-1H-
pyrazole-3-carboxylate (117) (275 mg, 0.75 mmol) and DIBAL
(1 M in DCM) (1.88 mL, 1.88 mmol) were combined in DCM
(5 mL) according to General Method 6a. Work-up afforded the
title compound, which was used in the next step without further
purification. 1H NMR (400 MHz, CDCl3): δ 9.93 (1H, s),
7.78−7.56 (4H, m), 6.42 (1H, s), 3.78−3.74 (4H, m), 2.93−




[isochromane-1,4′-piperidine] (78 mg, 0.38 mmol), 1-(4-
bromophenyl)-5-morpholino-1H-pyrazole-3-carbaldehyde
(121) (215 mg, 0.38 mmol), and sodium triacetoxyborohy-
dride (163 mg, 0.77 mmol) were combined in DCM (5 mL)
according to General Method 1. Work-up and purification
afforded the title compound (200 mg, 95%). 1H NMR (400
MHz, CDCl3): δ 7.76 (d, J = 8.8 Hz, 2H), 7.56 (d, J = 8.8 Hz,
2H), 7.24−7.10 (m, 4H), 5.97 (s, 1H), 3.92 (m, 2H), 3.78−
3.75 (m, 4H), 3.61 (s, 2H), 2.93−2.83 (m, 8H), 2.57−2.50 (m,
2H), 2.15−2.03 (m, 2H), 1.93 (d, J = 12.5 Hz, 2H).
4-(5-Morpholino-3-(spiro[isochromane-1,4′-piperidin]-1′-
ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (34). 1′-[[1-(4-Bro-
mophenyl)-5-morpholino-1H-pyrazol-3-yl]methyl]spiro-
[isochromane-1,4′-piperidine] (125) (150 mg, 0.29 mmol),
Pd(OAc)2 (2 mg, 0.01 mmol), Xantphos (7 mg, 0.01 mmol),
KF (42 mg, 0.72 mmol), and N-formylsaccharin (73 mg, 0.34
mmol) were combined in DMF (2 mL) according to General
Method 5. Work-up and purification afforded the title
compound (8 mg, 5%). HRMS (ESI) m/z: calcd for
C28H33N4O4 [M + H
+], 498.2502; found, 489.2498. 1H NMR
(400 MHz, D6-DMSO): δ 8.05−7.95 (m, 4H), 7.23−7.08 (m,
4H), 6.05 (s, 1H), 3.82 (dd, J = 5.4, 5.4 Hz, 2H), 3.70 (dd, J =
4.5, 4.5 Hz, 4H), 3.46 (s, 2H), 2.84 (dd, J = 4.5, 4.5 Hz, 4H),
2.75−2.71 (m, 4H), 2.41−2.33 (m, 2H), 1.97−1.90 (m, 2H),
1.78 (d, J = 12.7 Hz, 2H).
Synthesis of 4-(5-Cyclopropyl-3-((6-fluorospiro-
[isochromane-1,4′-piperidin]-1′-yl)methyl)-1H-pyrazol-1-yl)-
benzoic Acid (35) (Scheme 2). 4-(5-Cyclopropyl-3-((6-
fluorospiro[isochromane-1,4′-piperidin]-1′-yl)methyl)-1H-
pyrazol-1-yl)benzoic Acid (35). 6-Fluorospiro[isochromane-
1,4′-piperidine] (50) (216 mg, 0.98 mmol), 4-(5-cyclopropyl-
3-formyl-1H-pyrazol-1-yl)benzoic acid (85) (250 mg, 0.98
mmol), and sodium triacetoxyborohydride (414 mg, 1.95
mmol) were combined in DCM (4 mL) according to General
Method 1. Work-up and purification afforded the title
compound (261 mg, 57%). LCMS (ESI) m/z: 462 (M +
H)+. HRMS (ESI) m/z: calcd for C27H29FN3O3 [M + H
+],
462.2193; found, 462.2220. 1H NMR (500 MHz, CDCl3): δ
8.07 (d, J = 8.5 Hz, 2H), 7.52 (d, J = 8.5 Hz, 2H), 7.25 (dd, J =
8.7, 5.5 Hz, 1H), 6.87 (td, J = 8.7, 2.7 Hz, 1H), 6.78 (dd, J = 9.2,
2.7 Hz, 1H), 6.06 (s, 1H), 3.97 (s, 2H), 3.90 (t, J = 5.5 Hz, 2H),
3.41 (d, J = 10.7 Hz, 2H), 2.94 (t, J = 12.2 Hz, 2H), 2.85−2.79
(m, 2H), 2.54 (td, J = 13.9, 4.0 Hz, 2H), 1.99 (d, J = 13.9 Hz,
2H), 1.86−1.78 (m, 1H), 0.99−0.93 (m, 2H), 0.74−0.69 (m,
2H).
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Nxumalo, W.; Khanye, S. D.; Rullas, J.; Ortega, F.; Jimeńez, E.; Peŕez-
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